Clinical Trials

Clinical Trials Office

Code Clinical Trial Title Phase
MM-398-01-03-04 RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy. I
2SMALL Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-Based Chemotherapy. I
CA209-358 Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab.
(BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors
I
D419NC00001 Estudio de fase I de durvalumab e IPH2201 en pacientes adultos con tumores sólidos avanzados seleccionados. I
4010-01-001 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors. I
WO39409 A phase Ib combination study of rucaparib (CO-338) and atezolizumab (MPDL3280A) in patients with advanced gynecologic cancers and triple-negative breast cancer. I
BGB-290-103 A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors. I
YO40482 A PHASE Ib STUDY OF COBIMETINIB ADMINISTERED IN COMBINATION WITH NIRAPARIB, WITH OR WITHOUT ATEZOLIZUMAB, TO PATIENTS WITH ADVANCED PLATINUM-SENSITIVE OVARIAN CANCER. I
0402 A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in
Combination with Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin, in Adults with Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer.
I
3113001 Seguridad y tolerabilidad de dosis únicas y repetidas de ODM-203: primer estudio en el ser humano, abierto, no aleatorizado, multicéntrico, no controlado y con aumento progresivo de la dosis en pacientes con tumores sólidos avanzados. I
AMC303-01 A safety, tolerability and pharmacokinetic dose escalation and expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin? I
MK7339-002 Estudio de fase 2 de olaparib en monoterapia en participantes con cáncer avanzado positivo para la mutación del sistema de reparación por recombinación homóloga (HRRm) o déficit del sistema de recombinación homóloga (DRH) tratados previamente. Basket  
SGNTV-001 Estudio de fase 2, abierto, de tisotumab vedotina en tumores sólidos con enfermedad localmente avanzada o metastásica. Basket  
Debio 1143-106 SMARTPLUS-106: Debio 1143 a SMAC Mimetic In Combination With Nivolumab In Patients Failing Prior PD-1/PD-L1 Treatment: A Basket Trial. A dose-optimization, exploratory phase Ib/II study to assess safety and efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) mimetic Debio 1143, when given in combination with the anti-PD-1 antibody nivolumab in patients with specific solid tumors who have progressed during or immediately after anti-PD-1/PD-L1 treatment. Basket  
BLU-285-1101 A Phase 1 Study of BLU-285 in Patients with Gastrointestinal Stromal Tumors (GIST) and other Relapsed and Refractory Solid Tumors. I
TRASTS Ensayo clinico Fase I-II, abierto, prospectivo y muticéntrico, que explora la combinación de Trabectedina y Radioterapia en pacientes con Sarcoma de tejidos Blandos. I
INCB 59872-103 An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma. I
GEIS 58 OLATRASTS Ensayo clínico de fase I con Olaratumab más Trabectedina en pacientes con sarcoma de tejidos blandos avanzado. I
GO39374 A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY EVALUATING THE SAFETY, TOLERABILITY, AND
PHARMACOKINETICS OF GDC-0077 AS A SINGLE AGENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE AND TARGETED THERAPIES IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT HORMONE-RECEPTOR POSITIVE BREAST CANCER.
I
C0541001 A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06804103 IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) POSITIVE SOLID TUMORS. I
MEN1611-01 Estudio abierto, multicéntrico, de fase Ib, de escalado de dosis, de MEN1611, un inhibidor de PI3K combinado con trastuzumab ± fulvestrant, en sujetos con cáncer de mama irresecable y localmente recurrente (avanzado) o metastásico (a/m) HER2 positivo con mutación PIK3CA que ha progresado con un tratamiento basado en anti-HER2. I
PUMA NER-5201 An Open-Label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal
Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR gene amplification.
I
BP39365 ESTUDIO DE FASE IB MULTICÉNTRICO, ABIERTO, RANDOMIZADO, DE ESCALADA DE DOSIS PARA EVALUAR LA SEGURIDAD, FARMACOCINÉTICA Y ACTIVIDAD TERAPÉUTICA DE RO6874281 EN COMBINACIÓN CON ATEZOLIZUMAB ± BEVACIZUMAB, TRAS TRATAMIENTO PREVIO CON OBINUTUZUMAB, EN PACIENTES CON CARCINOMA DE CÉLULAS RENALES AVANZADO Y/O METASTÁSICO NO RESECABLE. I
B9991023 A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES. I
INCMGA0012-203 A Phase 2 Study of INCMGA00012 (PD-1 inhibitor) in Participants With Selected Solid Tumors (PODIUM-203). Basket  
CLXH254X2101 Estudio fase I, de búsqueda de dosis de LXH254 oral en pacientes adultos con tumores sólidos avanzados portadores de alteraciones en la vía de señalización MAPK. I
ARRAY-162-202 An Open-label Phase 1b/2 Study of Binimetinib Administered in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Patients with Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer with RAS Mutation I
GEMCAD 1602 A single arm Phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated mismatch
repair-proficient (MSS) metastatic colorectal cancer patients.
I
M15-913 An Open Label Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies. I
MK3475-158 Ensayo clínico de evaluación de biomarcadores predictivos con pembrolizumab (MK-3475) en pacientes con tumores sólidos avanzados (KEYNOTE 158). Basket  
PRN1371-001 A Phase 1 Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR1-4 Kinase Inhibitor, in Adult Patients with
Advanced Solid Tumors, followed by an Expansion Cohort in Patients with FGFR1, 2, 3, or 4 Genetic Alterations.
I
GO30103 A PHASE Ia/Ib OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MTIG7192A AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS. I
MK4280-001 A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors. I
PM14-A-001-17 Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors. I
KO-ERK-001 Un primer ensayo en humanos de fase I de KO-947 en malignidades no hematológicas
localmente avanzadas, no reseccionableso metastásicas
recidivantes y/o refractarias.
I
CP-MGA012-01 A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors. I
5225101 A Phase Ib Study to Evaluate the Safety, Tolerability and Efficacy of Gatipotuzumab and Tomuzotuximab Combination in Patients with EGFR-Positive Metastatic Solid Tumors. I
W00101-IV-1-01 Estudio abierto en fase I/II de aumento escalonado de la dosis y ampliación de la dosis de una infusión intravenosa de W0101, un conjugado anticuerpo-fármaco, en pacientes con tumores sólidos avanzados o metastásicos.
Estudio abierto, multicéntrico, internacional.
I
CB103-C-101 A PHASE I/IIA, MULTI-CENTRE, OPEN-LABEL, DOSE-ESCALATION STUDY WITH EXPANSION ARMS TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CB-103 ADMINISTERED ORALLY IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMOURS AND HAEMATOLOGICAL  ALIGNANCIES CHARACTERISED BY ALTERATIONS OF THE NOTCH SIGNALLING PATHWAY . I
MEN1309-01 OPEN-LABEL, MULTICENTER, PHASE I DOSE ESCALATION STUDY OF MEN1309, A CD205 ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH CD205-POSITIVE METASTATIC SOLID TUMORS AND NON-HODGKIN LYMPHOMA. I
CLHC165X2101 A Phase I/Ib, open-label, multi-center dose-escalation and dose-expansion study of the safety and tolerability of intratumorally administered LHC165 single agent and in combination with PDR001 in patients with advanced malignancies. I
BLU-667-1101 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors. I
BGB-A317/BGB-290 Estudio en fase I/Ib, abierto, de dosis múltiples, con aumento y ampliación de la dosis para investigar la seguridad, la farmacocinética y la actividad antitumoral del anticuerpo monoclonal anti-PD-1 BGB-A317 en combinación con el inhibidor de la PARP BGB-290 en sujetos con tumores sólidos en estadio avanzado I
SRA737-02 Ensayo en fase I/II de SRA737 (un inhibidor de Chk1) administrado por vía oral en combinación con gemcitabina más cisplatino o gemcitabina únicamente en pacientes con cáncer avanzado. I
AG270-C-001 Estudio Fase I de AG-270 en el tratamiento de sujetos con tumores sólidos avanzados o linfoma con deleción homocigótica de MTAP. I
MSC-1-101 A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MSC-1 in Patients with Advanced Solid Tumors. I
CA022-001 Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors. I
LOXO-EXT-17005 Estudio en fase I/II del inhibidor de la actividad de la TRK LOXO-195 en pacientes adultos y pediátricos que padezcan un cáncer portador de genes de fusión NTRK tratado previamente. I
LOXO-RET-17001 A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medularry Thyroid Cancer, and Other Tunors with Increased RET Activity. I
GCT1029-01 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1029 in patients with malignant solid tumors. I
204686 A Phase I, Open-Label Study of GSK1795091 Administered in Combination with Immunotherapies in Participants with Advanced Solid Tumors. I
J1F-MC-JZFA A Phase 1a/1b Study of LY3405105 Administered to Patients with Advanced Solid Tumors. I
C2321001 ESTUDIO DE FASE I DE AUMENTO GRADUAL DE LA DOSIS Y DE COHORTES EXPANDIDO DE PF-06821497 EN EL TRATAMIENTO DE PACIENTES ADULTOS CON CÁNCER DE PULMÓN MICROCÍTICO (CPM) RECIDIVANTE O RESISTENTE, CÁNCER DE PRÓSTATA RESISTENTE A LA CASTRACIÓN (CPRC) Y LINFOMA FOLICULAR (LF). I
ACT15377 Estudio en fase 1/2, abierto, multicéntrico, para evaluar la seguridad, eficacia preliminar y farmacocinética de isatuximab (SAR650984) en combinación con atezolizumab o solo isatuximab en pacientes con enfermedades malignas avanzadas. I
INCB 01158-101 Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (formerly known as CB-1158) as a Single Agent and in Combination with Immune Checkpoint Therapy in Patients with vanced/Metastatic Solid Tumors. I
2102-ONC-102 A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation. I
ICO-VCN-H&N-2018 A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination With Durvalumab (MEDI4736) in Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck. I
GCT1046-01 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects
with malignant solid tumors.
I
20140318 Estudio de fase 1b/2 multicéntrico y abierto para evaluar la seguridad de talimogene laherparepvec inyectado en tumores hepáticos en monoterapia o combinado con pembrolizumab sistémico (MASTERKEY-318). I
8374-CL-0101 A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors. I
NBTXR3/102 ESTUDIO DE FASE I DE AUMENTO ESCALONADO/AMPLIACIÓN DE LA DOSIS DE NBTXR3 ACTIVADO MEDIANTE RADIOTERAPIA DE INTENSIDAD MODULADA EN PACIENTES CON CARCINOMA DE CÉLULAS ESCAMOSAS LOCALMENTE AVANZADO EN LA CAVIDAD BUCAL O LA OROFARINGE. I
SC103 A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors. I
CTNO155B12101 A Phase Ib, open-label, multi-center study to characterize the safety, tolerability, and preliminary efficacy of TNO155
in combination with spartalizumab or ribociclib in selected malignancies.
I
NP41300 AN OPEN LABEL, MULTICENTER, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE SAFETY/TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PRELIMINARY ANTI TUMOR ACTIVITY OF RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
SL01-DEL-101 Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects with Advanced Solid Tumors or Lymphomas. I
LOXO-TRK-15002 A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors. Basket  
RXDX-101-02 An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements. Basket  
INCAGN1876-201 Estudio de fase I/II sobre la seguridad, la tolerabilidad y la eficacia de INCAGN01876 en combinación con inmunoterapias en sujetos con neoplasias malignas avanzadas o metastásicas. Basket  
CNIR178X2201 Estudio fase 2, multicéntrico, abierto, de NIR178 en combinación con PDR001, en pacientes con tumores sólidos avanzados seleccionados y linfoma no Hodgkin. Basket  
CA209-848 A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H). Basket  
Debio1347-201 Ensayo "basket" de fase II del paninhibidor del FGFR selectivo por vía oral Debio 1347 en pacientes con tumores sólidos que presentan una fusión de FGFR1, FGFR2 o FGFR3. Basket  
EMR200647-001 Ensayo de fase I, abierto, con dosis múltiples ascendentes, para investigar la seguridad, tolerabilidad, farmacocinética, y actividad biológica y clínica de MSB0011359C en sujetos con tumores sólidos metastásicos o localmente avanzados y expansión a indicaciones seleccionadas. I
63723283LUC1001 Estudio de primera administración en humanos, abierto, Fase 1/2 para evaluar la seguridad, farmacocinética, farmacodinámica y la actividad clínica de JNJ-63723283, un anticuerpo monoclonal Anti-PD1 en sujetos con cáncer avanzado. I
WIN001 Survival Prolongation by Rationale INnovative Genomics (SPRING): A proof of concept study to explore safety and efficacy of tri-therapy approach in advanced/metastatic NSCLC and retrospectively assess the ability of integrated genomics and transcriptomics to match patients to the combination. I
SYM015-01 Ensayo de fase 1a/2a, abierto y multicéntrico, para investigar la seguridad, tolerabilidad y actividad antitumoral de dosis repetidas de Sym015, una mezcla de anticuerpos monoclonales dirigida frente al receptor MET, en pacientes con tumores malignos sólidos en fase avanzada. I
CPDR001C2101 Phase Ib, multicenter, open label study of PDR001 in combination with platinum-doublet chemotherapy in PD-L1unselected, metastatic NSCLC patients. I
BO39610 ESTUDIO EN PARAGUAS DE FASE Ib/II, SIN ENMASCARAMIENTO, MULTICÉNTRICO Y ALEATORIZADO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE COMBINACIONES DE TRATAMIENTOS BASADOS EN MÚLTIPLES INMUNOTERAPIAS EN PACIENTES CON CARCINOMA DE PULMÓN NO MICROCÍTICO METASTÁSICO (MORPHEUS PULMONAR). I
IO102-012 Estudio en fase I/II, abierto, aleatorizado para investigar la seguridad y la eficacia de IO102 en combinación con pembrolizumab, con o sin quimioterapia, como tratamiento de primera línea para pacientes con cáncer de pulmón no microcítico metastásico. I
Brigatinib-1001 A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors. I
BP40657 ESTUDIO FASE IB/II DE DOS PARTES PARA INVESTIGAR LA FARMACOCINÉTICA, EFICACIA Y SEGURIDAD DEL ATEZOLIZUMAB SUBCUTÁNEO EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO ESTADIO IV. I
AC00102014-101 Estudio en fase I, multicéntrico y abierto de seguridad, farmacocinética y eficacia preliminar del inhibidor del EGFR que evita el gen natural, AC0010MA (abivertinib maleate), en pacientes adultos con cáncer de pulmón no microcítico (CPNM) con EGFRmut y la mutación adquirida T790M previamente tratado. I
61186372EDI1001 A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer. I
D7980C00001 A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics
Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects with Advanced Solid Tumors.
I
XL184-021 (PULMON) A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors. I
CLXH254X2102 A Phase Ib, open-label, multicenter study of oral LXH254- centric combinations in adult patients with advanced or
metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer or NRAS mutant melanoma.
I
73841937NSC2001 A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients with EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC). I
CA223-001 A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors. Basket  
BP40234 AN OPEN-LABEL, MULTICENTER, PHASE II STUDY TO EVALUATE THE THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE, CONSISTING OF INTERLEUKIN-2 VARIANT (IL-2V) TARGETING FIBROBLAST ACTIVATION PROTEIN-Α (FAP), IN COMBINATION WITH ATEZOLIZUMAB (ANTI-PD-L1), ADMINISTERED INTRAVENOUSLY, IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. Basket  
BP41054 AN OPEN-LABEL, MULTICENTER, PHASE IB STUDY TO EVALUATE SAFETY AND THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE, CONSISTING OF INTERLEUKIN-2 VARIANT (IL-2V) TARGETING FIBROBLAST ACTIVATION PROTEIN-Α (FAP), IN COMBINATION WITH PEMBROLIZUMAB (ANTI-PD-1), IN PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED AND/OR METASTATIC MELANOMA. I
MK3475-555 Estudio clínico de fase 1 aleatorizado de pembrolizumab (MK-3475) para evaluar la biodisponibilidad relativa de la inyección subcutánea frente a la infusión intravenosa en participantes con melanoma avanzado (KEYNOTE-555). I
NP40435 AN OPEN LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION, PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ANTI TUMOR ACTIVITY OF RO7121661, A PD-1/TIM-3 BISPECIFIC  NTIBODY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
IOV-COM-202 A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors. Basket  
CLGK974X2101 ESTUDIO FASE I, ABIERTO, DE ESCALADA DE DOSIS DE LGK974 ORAL, EN PACIENTES CON ENFERMEDADES MALIGNAS DEPENDIENTES DE LIGANDOS DE WNT2 I
CL1-95005-001 Estudio de fase I de escalada de dosis con S 95005 (TAS-102) en combinación con oxaliplatino (TAS-OX) en cáncer colorrectal metastásico. I
1401-0001 An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 905677 administered intravenously in patients with advanced solid tumours. I
MCLA-158-CL01 Phase 1 dose escalation and cohort expansion study evaluating single-agent MCLA-158 in metastatic colorectal cancer and other advanced solid tumors. I
CPDR001X2102 "Estudio de fase Ib, multicéntrico, abierto para determinar la seguridad, tolerabilidad y farmacodinámica (PD) de PDR001 en
combinación con LCL161, everolimus (RAD001) o panobinostat (LBH589)".
I
BAY 1163877/19774 A multicenter Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and recommended Phase 2 dose (RP2D)of the combination of rogaratinib and copanlisib in patients with FGFR-positive refractory, locally advanced or metastatic solid tumors. I
CP-MGD013-01 A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms. I
INCB 54828-207 A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207). Basket  
CC-90010-ST-001 A PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-90010 IN SUBJECTS WITH ADVANCED SOLID TUMORS AND RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMAS. I
3121001 Safety and pharmacokinetics of ODM-207 in patients with selected advanced solid tumours: an open-label, non-randomised, uncontrolled, multicentre, first-in-human study. I
CTNO155X2101 An open-label, multi-center, phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumors. I
64619178EDI1001 Estudio de primera administración en humanos, fase I, abierto, sobre la seguridad, farmacocinética y farmacodinamia de JNJ-64619178, un inhibidor de la proteína arginina-metiltransferasa-5 (PRMT5) en pacientes con cánceres avanzados. I
KO-TIP-001 An Open Label Phase II Study of Tipifarnib in Advanced NonHematological Malignancies with HRAS Mutations. Basket  
VHIO17002 Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours. Basket  
CC-90011-ST-001 A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-90011 IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN’S LYMPHOMAS. I
D2615C00001 An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY). I
204697 Estudio de fase IB, abierto, de aumento escalonado y expansión de la dosis, para investigar la seguridad, la farmacocinética, la farmacodinámica y la actividad clínica de GSK525762 en combinación con tratamiento de privación androgénica y otros agentes en sujetos con cáncer de próstata resistente a la castración (CRPC). I
64091742PCR2002 Estudio fase 1b-2 de Niraparib en combinación con terapias para el tratamiento del cáncer de próstata metastásico resistente a castración. I
56021927PCR2032 Estudio de fase Ib, abierto y multicéntrico de JNJ-63723283, un inhibidor de PD-1 administrado en combinación con apalutamida a pacientes con cáncer de próstata metastásico resistente a la castración I
A206T-G01-001 A Phase 1/2 open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligand therapy in patients with prostate specific membrane antigen (PSMA) positive (68Ga-PSMA-R2) progressive metastatic castration-resistant prostate cancer, following previous systemic
treatment.
I
BO40933 A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF IPATASERTIB IN COMBINATION WITH RUCAPARIB IN PATIENTS WITH ADVANCED BREAST, OVARIAN, OR PROSTATE CANCER. I
D6500C00001 A Phase I, Open-Label Study to Assess the Safety, Tolerability,Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD0156 Monotherapy or in Combination with either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients with Advanced Malignancies. I
D4620C00001 A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients with Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTENdeficient/ mutated or PIK3CB mutated/amplified Advanced Solid Malignancies, with Expansion to Assess the Pharmacodynamic Activity of AZD8186. I
CA012-004 Estudio fase 1/2a de BMS-986178 administrado en monoterapia y en combinación con nivolumab o ipilimumab en tumores sólidos avanzados. I
DEBIO 1347-101 A phase I, gene alteration-based, open label, multicenter study of oral Debio1347 (CH5183284) in patients with advanced solid malignancies, whose tumours have an alteration of the FGFR 1, 2 or 3 genes. I
TPU-TAS-120-101 A DOSE-FINDING PHASE 1 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS WITH OR WITHOUT FIBROBLAST GROWTH FACTOR/RECEPTOR (FGF/FGFR)-RELATED ABNORMALITIES FOLLOWED BY A PHASE 2 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS OR MULTIPLE MYELOMA WITH FGF/FGFR-RELATED ABNORMALITIES. I
TED13751 Estudio de primera administración en humanos para evaluar la seguridad, farmacocinética y actividad antitumoral de SAR408701 en pacientes con tumores sólidos avanzados. I
PCYC-1128-CA A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors. I
CO39083 A PHASE IB OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND PHARMACOKINETICS
OF COBIMETINIB IN COMBINATION WITH BEVACIZUMAB AND IMMUNOTHERAPY WHEN ADMINISTERED IN PATIENTS WITH GASTROINTESTINAL AND OTHER TUMORS.
I
GO39733 A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS. I
BP40087 ESTUDIO DE FASE IA/IB, ABIERTO, MULTICÉNTRICO, DE ESCALADA DE DOSIS, PARA EVALUAR LA SEGURIDAD, LA FARMACOCINÉTICA Y LA ACTIVIDAD ANTITUMORAL PRELIMINAR DE RO7122290, UN LIGANDO 4-1BB (CD137L) DIRIGIDO CONTRA LA PROTEÍNA α DE ACTIVACIÓN DE FIBROBLASTOS (FAP), CON O SIN PRETRATAMIENTO CON OBINUTUZUMAB, EN PACIENTES CON TUMORES SÓLIDOS AVANZADOS Y/O METASTÁSICOS, EN MONOTERAPIA O EN COMBINACIÓN CON ATEZOLIZUMAB, SEGUIDO DE COHORTE(S) DE EXPANSIÓN ESPECÍFICA(S) DEL TUMOR. I
BP40092 A FIRST-IN-HUMAN, OPEN-LABEL,MULTICENTER, DOSE-ESCALATION PHASE I CLINICAL STUDY OF SINGLE-AGENT RO7172508 IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC CEA-POSITIVE SOLID TUMORS. I
CO40939 A PHASE Ib, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMAKOKINETICS OF RO6958688 IN COMBINATION WITH ATEZOLIZUMAB AFTER PRETREATMENT WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC, MICROSATELLITE-STABLE COLORECTAL ADENOCARCINOMA WITH HIGH CEACAM5 EXPRESSION. I
MO29518 AN OPEN-LABEL, MULTICOHORT, PHASE II STUDY OF MPDL3280A IN ADVANCED SOLID TUMORS. Basket  
CA017-003-II Estudio fase 1/2a de BMS-986205 administrado en combinación con nivolumab (BMS-936558, anticuerpo monoclonal anti-PD-1) en tumores malignos avanzados. Basket  
TO-TAS0728-101 Estudio multicéntrico, abierto, en fase I/II para investigar la seguridad, farmacocinética y eficacia de TAS0728, un inhibidor oral de la unión covalente de HER2 en sujetos con tumores sólidos avanzados con anomalías en HER2 o HER3. Basket  
I7W-MC-JQBA A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors. I
BP29842 An open-label, multicenter, dose-escalation, Phase I study to evaluate safety, pharmacokinetics, and therapeutic activity of
RO6874281, an immunocytokine consisting of interleukin 2 variant (IL-2v) targeting fibroblast activation protein-á (FAP), in patients with advanced and/or metastatic solid tumors.
I
CA224-020 A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody Nivolumab, BMS-936558) in Advanced Solid Tumors. I
CFAZ053X210 1 Estudio de fase I, abierto, multicéntrico, de escalado de dosis de FAZ053 como agente único y en combinación con PDR001 en pacientes adultos con tumores malignos avanzados. I
204691 Estudio de fase I abierto de GSK3359609 en monoterapia y en combinación con fármacos antineoplásicos en sujetos con determinados tumores sólidos avanzados. I
INCAGN 1949 -101 A Phase 1/2 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors. I
VHIO-PBF-999-01 Phase I/Ib trial of single agent PBF-999 in solid tumour advanced cancer. I
D081EC00001 Estudio en fase I, abierto, de 2 partes, multicéntrico, para evaluar la seguridad, tolerabilidad y eficacia de olaparib en combinación con carboplatino; Parte A: aumento escalonado de la dosis de olaparib en combinación con carboplatino en pacientes con cáncer de mama avanzado HER-2 negativo; seguida de Parte B: fase de expansión de olaparib en combinación con carboplatino para el tratamiento neoadyuvante de pacientes con cáncer de mama avanzado HER-2negativo que presentan mutaciones BRCA1/2 en la línea germinal. I
B9991032 A PHASE 2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH BRCA OR ATM MUTANT TUMORS. Basket
SOLTI-1503 Combination of Talimogene Laherparepvec with Atezolizumab in residual breast cancer following standard neoadjuvant multi-agent chemotherapy (PROMETEO TRIAL). 0
201973 A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer. I
1280.18 Estudio abierto, de fase Ib, de escalado de dosis, para evaluar la seguridad y tolerabilidad de xentuzumab y abemaciclib en pacientes con tumores sólidos localmente avanzados o metastásicos y en combinación con hormonoterapia en pacientes con cáncer de mama localmente avanzado o metastásico positivo para receptores hormonales (RH+) y negativo para HER2, seguido por cohortes de expansión. I
CO40115 A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER (MORPHEUS TNBC). I
D8530C00001 A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast CancerA Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast Cancer. I
CADPT01A12101C A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer. I
ZEN003694-004 A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer. I
CO41012 AA PHASE IB/III STUDY OF IPATASERTIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN HORMONE RECEPTOR POSITIVE AND HER2 NEGATIVE LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER. I
YO39609 A phase Ib/II, open-label, multicenter, randomized, umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer (morpheus-gastric cancer). I
MCLA-128-CL01 A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors. Basket  
BP29889 AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE IB STUDY WITH EXPANSION COHORTS TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND THERAPEUTIC ACTIVITY OF  O7009789 (CD40 AGONISTIC MONOCLONAL ANTIBODY) IN COMBINATION WITH VANUCIZUMAB (ANTI-ANG2 AND ANTI-VEGF BI-SPECIFIC MONOCLONAL ANTIBODY) IN PATIENTS WITH METASTATIC SOLID TUMORS. I
I8X-MC-JECA A Phase 1 Study of LY3200882 in Patients with Solid Tumors. I
GO39932 A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC 9545 Alone or In Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer. I
GO40987 A PHASE I, MULTICENTER, OPEN-LABEL PREOPERATIVE SHORT-TERM WINDOW STUDY OF GDC-9545 IN POSTMENOPAUSAL WOMEN WITH STAGE I-III OPERABLE, ESTROGEN RECEPTOR-POSITIVE BREAST CANCER. I
BAY 1163877 / 19131 An international, multicenter, Phase 1b/2 study of rogaratinib (BAY 1163877) in combination with atezolizumab as first-line treatment in cisplatin-ineligible patients with FGFR-positive locally advanced or metastatic urothelial carcinoma. I
XL184-021 A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors. I
B-701-U22 A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined with Pembrolizumab in Subjects with Locally Advanced or Metastatic Urothelial Carcinoma who have Progressed Following Platinum-basedChemotherapy. I
WO39613 A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY (MORPHEUS-mUC). I
BLU-554-1101 A Phase 1 Study to Assess the Safety, Tolerability,
Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma and Cholangiocarcinoma.
I
CC-122-HCC-002 A PHASE 1/2, MULTICENTER, OPEN-LABEL, DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF CC-122 IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC). I
H3B-6527-G000-101 An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma. I
BAY94-9343/15834 Estudio de fase Ib de múltiples indicaciones con anetumab ravtansina (BAY-94-9343) en pacientes con cáncer
avanzado o recurrente que expresan mesotelina?
I
CTMT212X2106 Estudio fase I/II de seguridad y eficacia de ribociclib (LEE011) en combinación con trametinib (TMT212), en pacientes con tumores sólidos avanzados o metastásicos. I
P-VCNA-001 A phase I, multicenter, open-label, dose escalation study of intravenous administration of VCN-01 oncolytic adenovirus with or without gemcitabine and Abraxane® in patients with advanced solid tumors. I
I5B-MC-JGDP A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer. I
WO39608 A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MORPHEUS-PANCREATIC CANCER). I
AXI-IIG-0 2 A PHASE II RANDOMIZED DOUBLE-BLIND STUDY OF SANTOSTATIN LAR IN COMBINATION WITH AXITINIB VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED WELL-DIFFERENTIATED NEUROENDOCRINE CARCINOMAS OF NON-PANCREATIC ORIGIN (CARCINOIDS). II
CBGJ398 X2204 Estudio fase II, multicéntrico, con un único brazo de tratamiento, de BGJ398 oral en pacientes adultos con colangiocarcinoma avanzado o metastásico, con fusiones del gen FGFR2 u otras alteraciones genéticas del FGFR que han progresado o que son intolerantes a quimioterapia basada en platino. II
62113-55 115 A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment. II
TRASTS-II Ensayo clinico Fase I-II, abierto, prospectivo y muticéntrico, que explora la combinación de Trabectedina y Radioterapia en pacientes con Sarcoma de tejidos Blandos. II
APR-407 PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246. II
NVALT-15 Estudio Fase II con BIBF1120, un inhibidor oral del factor 1 de crecimiento de fibroblastos, como tratamiento de segunda línea en pacientes con cáncer de pulmón no microcítico y amplificación del gen del receptor 1 del factor de crecimiento de fibroblasto. II
CEGF816 X2201C Estudio de fase II, multicéntrico, abierto de EGF816 en combinación con nivolumab en pacientes adultos con cáncer de pulmón de células no pequeñas con mutación del EGFR y de INC280 en combinación con nivolumab en pacientes adultos con cáncer de pulmón de células no pequeñas con cMet positivo. II
SOLTI 13 03 PATRICIA: Ensayo clínico fase II de la combinación de palbociclib y trastuzumab con o sin letrozol en pacientes postmenopáusicas con cáncer de mama localmente avanzado o metastásico HER2-positivo previamente tratado. II
ET-FES ST UDY 174-01 Early prediction of efficacy of endocrine therapy in breast cancer: pilot study and validation with 18f fluoroestradiol (FES) CT/PET. II
RG-13-27 7 (rEECur) An international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. II
CINC280 A2201 Estudio de fase II, multicéntrico, de tres cohortes con el inhibidor oral de cMET, INC280, en pacientes adultos con cáncer de pulmón de células no pequeñas (NSCLC) avanzado y EGFR wild type (wt), que han recibido una o dos líneas previas de terapia sistémica para enfermedad avanzada/metastásico. II
GEIS 40 Phase II, multicenter, open label, prospective trial for the use of regorafenib as first line treatment for patients with KIT/PDGFR Wild Type GIST II
D5660C0 0004 A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. II
B999100 1 A phase 3, mulitcenter, multinacional, randomized, open-label, parallel-arm study of Avelumab* (MSB0010718C) plus best supportive care versus best supportive care alone as a maintenance treatment in patients wirh locally advanced or metastatic urothelial cancer whose disease did not progress after coppletion of first-line platinum-containing chemotherapy. II
GETNE-2 016-01 Estudio Fase II para evaluar la eficacia dek retratamiento con sunitinib en pacientes con tumores neuroendocrinos pancreáticos bien diferenciados G1/2 (pNET) avanzados o metastásicos que ya han fracasado a un tratamiento con sunitinib previo (Estudio RESUNET). II
MS20009 5-0022 Ensayo de fase II de un único grupo para investigar tepotinib en el adenocarcinoma pulmonar en estadio IIIB/IV con alteraciones por omisión del exón 14 de MET (METex14) tras fallar, como mínimo, un tratamiento activo anterior, incluido uno con doblete de platino. II
IRX-2 201 5A A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy with the IRX 2 Regimen in Patients with Newly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity. II
MYL-140 20-3001 Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer. II
GL0817-0 1 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (with Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients with High-Risk Squamous Cell Carcinoma of the Oral Cavity. II
ABT-C5-2 016 A phase I/II open label study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLC. II
SOLTI-14 02 Ensayo clínico de fase 2 de poliquimioterapia o letrozol más ribociclib (LEE001) como tratamiento neoadyuvante en pacientes posmenopáusicas con cáncer de mama de tipo luminal B y HER2 negativo. II
GEMCAD 1601 Tratamiento preoperatorio de inducción con 12 semanas de Panitumumab combinado con FOLFOX 6m en una población enriquecida (Quádruple Wild-Type) de pacientes con cáncer de recto de tercio medio mrT3 y fascia mesorrectal no invadida. II
MK3475- 365 Ensayo de fase Ib/II de tratamientos combinados con pembrolizumab (MK-3475) en el cáncer de próstata resistente a la castración metastásico (CPRCm) (KEYNOTE-365). II
POSEIDO N-II Phase I/prospective randomised phase II trial Of the Safety and Efficacy of tamoxifen in combination with the Isoform selective Pi3K inhibitor GDC-0032 compared with tamoxifen alONe in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment II
INCB 548 28-201 Estudio en fase II, abierto, en monoterapia y multicéntrico para evaluar la eficacia y la seguridad de INCB054828 en sujetos con carcinoma urotelial metastásico o irresecable quirúrgicamente portador de alteraciones del FGF/FGFR. II
CA209-64 8 Estudio fase 3, aleatorizado, de nivolumab más ipilimumab o nivolumab en combinación con fluorouracilo más cisplatino frente a fluorouracilo más cisplatino en pacientes con carcinoma de células escamosas de esófago avanzado irresecable, recurrente o metastásico, previamente no tratado. II
6409174 2PCR2001 A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies. II
BGBC008 A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the LungA Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with
Previously Treated Advanced Adenocarcinoma of the Lung.
II
MDV380 0-06 A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone). II
ESR 15-1 1561-61 A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with advanced neuroendocrine neoplasms of gastroenteropancreatic or lung origin (the DUNE trial). II
GEICAM 2015-06 Ensayo Clínico Fase II para analizar la Respuesta a Olaparib de pacientes con Metilación del Promotor del BRCA1 y/o 2 diagnosticadas de Cáncer de Mama Avanzado (Estudio COMETA-Breast). II
SYD985.0 02 A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer. II
ONT-380- 206 Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma. II
1613-LCG APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients. II
SOGUG-2 016-A- IEC(REN)-10 Estudio fase II para evaluar la eficacia y seguridad del tratamiento con sunitinib en pacientes con carcinoma renal de células claras metastásico que han progresado al tratamiento con inmunoterapia en primera línea. II
010580Q M MEDI4736 combinations in metastatic renal cell carcinoma (CALYPSO). II
BO29554 ESTUDIO DE FASE II/III, MULTICÉNTRICO, PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE MÚLTIPLES TERAPIAS DIRIGIDAS COMO TRATAMIENTO PARA PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO (CPNM) AVANZADO O METASTÁSICO PORTADORES DE MUTACIONES SOMÁTICAS ACCIONABLES DETECTADAS EN SANGRE (B-FAST: PRIMER ANÁLISIS DE SCREENING EN SANGRE). II
APR-486 PiSARRO-R: p53 Suppressor Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Phase II Study of Systemic Pegylated Liposomal Doxorubicin Chemotherapy With APR-246. II
CBYL719 X2402 A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of
alpelisib plus fulvestrant or letrozole in patients with
PIK3CA mutant, hormone receptor (HR) positive, HER2- negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment.
II
1200.283 Estudio de fase II, abierto y no aleatorizado de afatinib en combinación con pembrolizumab en pacientes con carcinoma de células escamosas de pulmón localmente avanzado o metastásico. II
MedOPP 096 - MO39229 Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. The PHERGain study. II
MK3475- 629 Estudio de fase 2, abierto, de un solo grupo, para evaluar la seguridad y la eficacia de pembrolizumab en participantes con carcinoma epidermoide cutáneo recurrente o metastásico (CEC R/M). II
TTD-14-0 5 Estudio fase I-II con Nab-paclitaxel (Abraxane®) y gemcitabina seguido de FOLFOX.
modificado (AG-mFOLFOX) en pacientes con cáncer de páncreas metastásico no tratado.
II
TTD-16-0 3 Randomised, multicentre, phase II pilot study to assess the efficacy and safety of treatment with FOLFIRI-aflibercept compared to initial treatment with FOLFIRI-aflibercept (for 6 cycles) followed by maintenance with 5FU-aflibercept, in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen. II
CA209-71 4 Estudio Fase 2, doble ciego, aleatorizado, de dos grupos, de Nivolumab en combinación con Ipilimumab frente a Nivolumab en combinación con Ipilimumab placebo en carcinoma de células escamosas de cabeza y cuello (CCECC)en recidiva o metastásico. II
PM60184 -B-002-17 Estudio Fase II, Multicéntrico, Abierto de PM060184 en Pacientes con Cáncer Colorrectal Avanzado tras Tratamiento Estándar. II
INCB 391 10-207 An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non–Small Cell Lung Cancer. II
D5161C0 0003 A multicentre, open-label, single-arm, molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treated with osimertinib. II
TDM452 9g/BO25430 AN OPEN-LABEL, MULTICENTER EXTENSION STUDY OF TRASTUZUMAB EMTANSINE ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OTHER ANTI-CANCER  THERAPIES IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH AND/OR F. HOFFMANN-LA ROCHE LTD-SPONSORED TRASTUZUMAB EMTANSINE STUDY. II
GETHI021 A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors presenting in  dulthood (GETHI021). II
VHIO160 01 - EORTC 1604 A phase II open-label study with the anti-PD-L1 Atezolizumab monoclonal antibody in combination with Bevacizumab in patients with advanced chemotherapy resistant colorectal cancer and MSI-like molecular signature . II
MCLA-12 8-CL02 Phase II study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA- 28/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive and low-HER2 expression MBC. II
MK3475- 495 A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475,SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT). II
GEIS-52 Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas. II
GEIS 39 “Ensayo fase II de nab-paclitaxel para el tratamiento de tumores desmoides y tumores desmoplásicos de células pequeñas y redondas y sarcoma de Ewing en recaída múltiple o refractarios”. II
GEIS 36 A phase 2, single arm, multi center trial evaluating the efficacy of the COmbination of Sirolimus and cYclophosphamide in metastatic or unresectable Myxoid liposarcoma and chOndrosarcoma. II
C-145-04 Estudio fase II, multicéntrico para evaluar la eficacia y la seguridad del uso de Linfocitos Autólogos Infiltrantes Tumorales (LN-145) en pacientes con Carcinoma de Cérvix recidivante, metastásico o persistente. II
ETOP12- 17 Estudio Fase II con un solo grupo que evalúa la actividad de alectinib para el tratamiento de CNPM avanzado con reordenamiento de RET en pacientes previamente tratados. II
I4D-MC-J TJN A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer. II
BAY 1163 877/17403 Estudio de fase 2/3 aleatorizado, abierto, multicéntrico para evaluar la eficacia y seguridad de Rogaratinib (BAY 1163877) comparado con quimioterapia en pacientes FGFR positivos con carcinoma urotelial metastásico o localmente avanzado que hayan recibido previamente quimioterapia con platino. II
CA209-9X 8 An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer. II
CA224-04 7 A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma. II
C-144-01 A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma. II
MEDOPP 089 A multicenter, international, non-controlled, phase II trial to identify the molecular mechanisms of resistance and sensitivity to palbociclib re-challenge upon progression to a palbociclib combination in ER-positive metastatic breast cancer patients (BioPER). II
D5336C0 0001 A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2) (VIOLETTE). II
D933IC00 003 Ensayo clínico fase II, aleatorizado, multicéntrico, doble ciego, internacional, comparativo para determinar la eficacia y la seguridad de durvalumab en combinación con olaparib para el tratamiento en primera línea, en pacientes con cáncer urotelial irresecable en estadio IV inelegibles para tratamiento con cisplatino. II
MK3475- 775 / E7080-G000-309 Ensayo de fase 3, abierto, multicéntrico y aleatorizado para comparar la eficacia y la seguridad de lenvatinib en combinación con pembrolizumab frente al tratamiento de elección del médico en pacientes con cáncer de endometrio avanzado. II
BGB-A31 7-208 A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients with Previously Treated Hepatocellular Unresectable Carcinoma. II
EF-30 HEPANOVA: A Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC). II
UC-0140/ 1606 UCBG-105-BIG 16-01 A phase II trial testing durvalumab combined with endocrine therapy in patients with ER+/HER2- breast cancer eligible for neoadjuvant endocrine therapy and who present CD8+ T cell infiltration after 4-6 weeks exposure to immune-attractant. II
VHIO170 01 VHIO17001 II
GO40290 A PHASE II, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED STUDY OF MTIG7192A, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB IN CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER. II
MS10007 0-0160 Estudio de fase II, multicéntrico, aleatorizado y abierto para evaluar la seguridad y la eficacia de avelumab con gemcitabina/carboplatino frente a quimioterapia con gemcitabina/carboplatino sola, en pacientes con carcinoma urotelial no resecable o metastásico que no hayan recibido terapia sistémica previa y que no sean aptos para la quimioterapia con cisplatino. II
CO-338-0 85 ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. II
SGN22E- 001 Estudio multicéntrico, de un solo grupo y abierto, de enfortumab vedotin (ASG-22CE) en el tratamiento de pacientes con cáncer urotelial localmente avanzado o metastásico que han recibido previamente inhibidores de los puntos de control (checkpoint inhibitor, CPI) inmunológicos. II
DS8201- A-J203 A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced colorectal cancer. II
M14-064 Phase 2 Study Comparing Efficacy and Safety of ABT-165 plus FOLFIRI vs Bevacizumab plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab. II
EORTC-1 525-LCG Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma
previously treated with chemotherapy - (Nivothym).
II
CX-839-0 08 A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC). II
MK3475- 799 Ensayo de fase 2 de pembrolizumab (MK-3475) en combinación con quimioterapia con doblete de platino y radioterapia para participantes con cáncer de pulmón no microcítico (CPNM) en estadio III irresecable y localmente avanzado (KEYNOTE-799). II
GECP17/ 02 A Phase II open-label multicenter exploratory study to assess efficacy of Pembrolizumab re-challange as second or further line in patients with advanced non - small cell lung cancer. II
ONCOS C 719 A randomised Phase II open-label study with a Phase Ib safety lead-in cohort of ONCOS-102, an immune-priming GM-CSF coding oncolytic adenovirus, and pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma. II
2002 Brigatinib en pacientes con cáncer de pulmón de células no pequeñas avanzado con linfoma anaplásico cinásico positivo (ALK+) cuyo cáncer ha progresado durante el tratamiento con alectinib o ceritinib. II
DS8201- A-U204 ESTUDIO EN FASE II, MULTICÉNTRICO, ABIERTO, DE 2 COHORTES DE TRASTUZUMAB DERUXTECÁN (DS-8201A), UN CONJUGADO ANTICUERPO-FÁRMACO (CAF) ANTI-HER2 PARA EL CÁNCER DE PULMÓN NO MICROCÍTICO (CPNM) IRRESECABLE Y/O METASTÁSICO CON MUTACIÓN O SOBREEXPRESIÓN DE HER2. II
W00090 GE201 Estudio en fase II, multicéntrico, abierto y de un solo grupo de encorafenib, binimetinib más cetuximab en sujetos con cáncer colorrectal metastásico con mutación BRAFV600E sin tratamiento previo. II
MK3475- 782 A Phase II Trial to Investigate Genetic Markers of Response to Pembrolizumab (MK-3475, SCH 900475) Combined with Chemotherapy as a First-line Treatment for Non-Small Cell Lung Cancer (KEYNOTE-782). II
I3Y-MC-J PCP Estudio de fase 2 abierto y aleatorizado, en el que se evalúa cómo influyen los alimentos en la tolerabilidad de abemaciclib en pacientes con cáncer de mama metastásico con receptores hormonales positivos y HER2 negativos para el que hayan recibido tratamiento previo II
CA025-00 6 A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination with Nivolumab (BMS-936558) with and without Chemotherapy in Patients with Advanced Pancreatic Cancer. II
1280-002 2 Xenera-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in
combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2-metastatic breast cancer and non-visceral disease.
II
GEMCAD 1701 Estudio aleatorizado de fase II para evaluar la eficacia de FOLFIRI + panitumumab en el tratamiento en segunda línea de pacientes con cáncer colorrectal metastásico RAS no mutado que han recibido FOLFOX + panitumumab en primera línea de tratamiento. II
GECP17/ 04 An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer with HRAS mutations. II
I5B-MC-J GDP-II A Phase 1b (Open-Label) / Phase 2 (Randomized,Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer. II
ISA101b- HN-01-17 A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Platin-Resistant Oropharyngeal Cancer (OPC). II
GECP17/ 05 Phase II non-randomized study of atezolizumab (mpdl3280a) in combination with carboplatin plus pemetrexed in patients who are chemotherapy-naïve and have stage IV non-squamous non-small cell lung cancer with asymptomatic brain metastasis. II
TACTI-00 2 (P015) TACTI-002 (Two ACTive Immunotherapeutics): A multicenter, open label, Phase II study in patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), or recurrent PD-X refractory NSCLC or with recurrent or metastatic squamous head and neck cancer (HNSCC) receiving the soluble LAG-3 fusion protein eftilagimod alpha (IMP321) in combination with pembrolizumab (PD-1 antagonist). II
MS20064 7-0037 A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer. II
M16VIB MoTriColor: A phase II study of vinorelbine in advanced BRAF-like colon cancer. II
I3Y-MC-J PCM A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate plus Prednisone with or without
Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer.
II
205801 A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants. II
D6070C0 0005 A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447)
with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal
Adenocarcinoma.
II
MedOPP 168 Effectiveness of olaparib plus trastuzumab in HER2-positive BRCA-mutated or Homologous Recombination Deficiency (HRD) advanced breast cancer patients .– The OPHELIA Study – II
SGNLVA- 002 Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of
Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer.
II
KO-TIP-0 07 El estudio AIM-HN y SEQ-HN: Estudio pivotal no comparativo de 2 cohortes para evaluar la eficacia de tipifarnib en pacientes con carcinoma de células escamosas de cabeza y cuello (CCECC) con mutaciones de HRAS (AIM-HN) y el impacto de las mutaciones de HRAS en la respuesta a las terapias sistémicas de primera línea para el CCECC (SEQ-HN). II
CA209-9 HX PROSTRATEGY: A multi-arm, multi-stage, randomized phase II/III trial of immunotherapy strategies in metastatic hormone-sensitive prostate cancer. II
SUNNIFO RECAST A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Standard of Care in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma. II
INCMGA 0012-202 A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy. II
FiHM006 Ensayo fase II para evaluar la evolución de la carga de mutación de KRAS por biopsia
líquida  en  pacientes  con  adenocarcinoma  ductal  pancreático  resecable  tratados  con
tratamiento neoadyuvante NALIRINOX.
II
INCMGA 0012-201 Estudio en fase II de INCMGA00012 en participantes con carcinoma de células de Merkel metastásico. II
MS20064 7-0047 A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolerant to First-line Platinum-Based Chemotherapy. II
MS20194 4-0170 A Phase IIa, single-arm, multicenter study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in participants with advanced squamous non-small-cell lung cancer. II
APX005 M-002 A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma. II
R2810-O NC-1540 A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH – 1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA. II
GETNE-T 1812 A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma-The DUTHY trial. II
CA224-06 0 Ensayo clínico fase 2, aleatorizado, abierto, de relatlimab (anti-LAG-3) y nivolumab en combinación con quimioterapia frente a nivolumab en combinación con quimioterapia como tratamiento de primera línea en pacientes con adenocarcinoma gástrico o de la unión gastroesofágica. II
AP32788- 15-101 A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer. II
BL-8040. PAC.201 A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE COMBINATION OF BL-8040 AND PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC PANCREATIC CANCER, THE COMBAT STUDY. II
M14-239 Estudio de fase II abierto para evaluar la seguridad y la eficacia de telisotuzumab vedotina (ABBV-399) en pacientes con cáncer de pulmón no microcítico c-Met+ tratado previamente. II
GEICO 78 -C ATOMICC A randomized, open label, phase II trial of Anti-PD1, TSR-042, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation. II
MEDOPP 199 NEOADJUVANT LETROZOLE AND PALBOCICLIB IN PATIENTS WITH STAGE II-IIIB BREAST CANCER, HR[+]/HER2[-] PHENOTYPE AND PRE-TREATMENT RECURRENCE SCORE® (RS) RESULT 18-25 OR 26-100 BY THE ONCOTYPE DX BREAST RS ASSAY. ANALYSIS OF RS AND PATHOLOGICAL CHANGES AT SURGERY (DxCARTES TRIAL) . II
MedOPP 068 International, multicenter, randomized, open-label, phase II clinical trial to evaluate the efficacy and safety of continuation of palbociclib in combination with second-line endocrine therapy in hormone receptor-positive/HER2-negative Advanced Breast Cancer patients who have achieved clinical benefit during first-line palbociclib-based treatment. (PALMIRA). II
CORT125 134-552 Estudio de fase II, aleatorizado, sin enmascaramiento y de 3 grupos de relacorilant en combinación con nab-paclitaxel en pacientes con cáncer de ovario, de trompas de Falopio o peritoneal primario recurrente y resistente al platino. II
BGB-290- 202 A Phase 2, Open-Label, Single-Arm Study of Pamiparib (BGB-290) for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Homologous Recombination Deficiency (HRD). II
BARBICA N BARBICAN: A randomised, open-label Phase II study to determine the contribution of ipatasertib to neoadjuvant hemotherapy plus atezolizumab in women with triple-negative breast cancer. II
ARRAY-8 18-202 Estudio de fase 2, abierto, de encorafenib + binimetinib en pacientes con cáncer de pulmón no microcítico con mutación BRAFV600E. II
GECP 18/ 02 A randomized phase II study of neo-adjuvant chemo/immunotherapy versus chemotherapy alone for the treatment of locally advanced and potentially resectable nonsmall cell lung cancer (NSCLC) patients. NADIM II. II
VHIO190 01 Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with respectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC) – MONEO Study. II
D9108C0 0001 A Phase 2, Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab Alone or in Combination with
Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Cell Lung Cancer (COAST).
II
GETNE-T 1913 A phase II study of platinum-doublet chemotherapy in combination with nivolumab as first-line treatment in subjects with unresectable, locally advanced or metastatic G3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or of unknown (UK) origin. II
SMS-047 2B A Randomized, Multicentre, Open-Label Controlled Phase II Trial of Foxy-5 as Neo-Adjuvant Therapy in Subjects with Wnt-5a Low Colon Cancer. II
DS8201- A-U205 A Phase 2, open-label, single-arm trial of trastuzumab deruxtecan (DS-8201a) in HER2-positive, unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen. II
D910CC0 0001 A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (COLUMBIA-1). II
EORTC-1 612-MG Tratamiento combinado dirigido (encorafenib y binimetinib) seguido de inmunoterapia combinada (ipilimumab y nivolumab) frente a inmunoterapia combinada inmediata en pacientes con melanoma irresecable o metastásico con mutación de BRAF V600: un estudio de EORTC aleatorizado de fase II (EBIN). II
GEM-180 2 Phase II, multicenter clinical trial to evaluate the activity of encorafenib and binimetinib administered before local treatment in patients with BRAF mutant melanoma metastatic to the brain. II
ODO-TE- B201 Un estudio multinacional, multicéntrico, fase 2 de tesetaxel más una dosis reducida de capecitabina en pacientes con HER2 negativo, receptor hormonal positivo, cáncer de mama localmente avanzado o metastásico que no han recibido previamente el tratamiento con taxane. II
APX005 M-010 A Phase II Multicenter, Open-label Study in Two Parallel-Groups to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M in Adults with Immunotherapy Naive Unresectable or Metastatic Melanoma. II
TAS-120- 201 A Phase 2 Study of TAS-120 in Metastatic Breast Cancer Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications. II
GEIS 41 A multicenter, phase Ib/II trial of selinexor in combination with imatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) . II
C-700-01 A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics,
Biological, and Clinical Activity of AGEN2034 in Subjects with Metastatic or Locally Advanced Solid Tumors, with
Expansion to Second Line Cervical Cancer.
II
B999102 3-II A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES. II
MS20009 5-0031 A Phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd
generation EGFR-tyrosine kinase inhibitor therapy.
II
TPU-TAS- 120-101-II TPU-TAS-120-101-II II
ISG-GEIS 10-01SARCOMAS DE PARTES BLANDAS LOCALIZADOS DE ALTO RIESGO DE EXTREMIDADES Y PARED DE TRONCO EN ADULTOS: UN ENFOQUE INTEGRADOR QUE INCLUYE QUIMIOTERAPIA ESTÁNDAR VS HISTOTIPO-DIRIGIDA NEOADYUVANTE.III
GETUG-AFU 23A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse.III
D081CC00006Ensayo fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, para evaluar la eficacia y la seguridad de olaparib frente a placebo como tratamiento adyuvante de pacientes con cáncer de mama HER2 negativo de alto riesgo y mutaciones germinales de BRCA1/2, que han finalizado el tratamiento local y la quimioterapia neoadyuvante o adyuvante.III
GBG-78- BIG1-13-NSABP-B-54Estudio fase III que evalúa palbociclib (PD-0332991), un inhibidor de quinasa dependiente de las ciclinas (CDK) 4/6, en pacientes con cáncer de mama primario con receptores hormonales positivos y HER2 normal y alto riesgo de recidiva tras quimioterapia neoadyuvante “PENELOPE B”.III
I3Y-MC-JPBLEstudio de fase 3, aleatorizado, doble ciego, controlado con placebo, en el que se evalúa fulvestrant en combinación o no con LY2835219, un inhibidor de las CDK4/6, en mujeres con cáncer de mama localmente avanzado o metastásico, receptor hormonal positivo,
HER2 negativo.
III
RG-11-152International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours.III
GETNE-1206Estudio abierto y aleatorizado para comparar la eficacia y la seguridad de everolimus seguido de quimioterapia con STZ-5FU tras la progresión o la secuencia invertida, quimioterapia con STZ-5FU seguida de everolimus tras la progresión, en tumores neuroendocrinos pancreáticos (TNEP) avanzados y progresivos (estudio SEQTOR).III
XL184-401Estudio aleatorizado y doble ciego para evaluar la eficacia y la seguridad de cabozantinib (XL184) con dosis de 60 mg/día en comparación con 140 mg/día en pacientes con cáncer medular de tiroides metastásico progresivo.III
MO29406A SINGLE-ARM OPEN-LABEL MULTI-CENTRE EXTENSION STUDY OF PERTUZUMAB ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS PREVIOUSLY ENROLLED IN A HOFFMANN-LA ROCHE-SPONSORED PERTUZUMAB STUDY.III
D5164C00001A Phase I/II Multi-centre Study of AZD8931 in Combination with Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Solid Tumours and in a Selected Population with Low HER2-expressing Locally Recurrent and/or Metastatic Breast Cancer (THYME).III
BR.31Ensayo Clínico Fase III, prospectivo, aleatorizado, doble ciego, de quimioterapia adyuvante con MEDI4736 versus placebo en pacientes con cáncer de pulmón no microcítico con resección completa.III
SSGXXIThree versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study.III
1203-GITCGINtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL.III
HALO-109-301Estudio de Fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico, de la forma PEGilada de la hialuronidasa recombinante humana (PEGPH20) en combinación con nabpaclitaxel y gemcitabina, comparados con placebo más nab-paclitaxel y gemcitabina, en sujetos con adenocarcinoma ductal pancreático en estadio IV con elevación de hialuronano no tratados previamente.III
MK3475-091Ensayo de fase III, aleatorizado, con el anticuerpo monoclonal anti-PD-1 pembrolizumab (MK-3475) en comparación con placebo en pacientes con CPNM en estadios iniciales tras la resección y la finalización del tratamiento adyuvante de referencia (PEARLS).III
A-US-52030-328A Phase 3, prospective, randomized, double-blind, multi-center study of the efficacy and safety of lanreotide Autogel/Depot 120 mg plus BSC vs. placebo plus BSC for tumor control in subjects with well differentiated, metastatic and/or unresectable, typical or atypical, lung neuroendocrine tumors.III
CA209-577"Estudio fase III, aleatorizado, multicéntrico, doble ciego de nivolumab adyuvante o placebo en sujetos con cáncer resecado de esófago o dela unión gastroesofágica!.III
CA209-274Estudio de fase 3 aleatorizado, doble ciego, multicéntrico, de nivolumab como tratamiento adyuvante frente a placebo en sujetos con Carcinoma urotelial invasivo de alto riesgo.III
ADXS001-02PHASE 3 STUDY OF ADXS11-001 ADMINISTERED FOLLOWING CHEMORADIATION AS ADJUVANT TREATMENT FOR HIGH RISK LOCALLY ADVANCED CERVICAL CANCER: AIM2CERV.III
PM1183-C-003-14Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinumcontaining Line (ATLANTIS Trial).III
OSE2101C301A randomized parallel group phase III trial of OSE 2101 as 2nd line after prior platinum-based chemotherapy failure or as 3rd line after platinum-failure and checkpoint inhibitor-failure, compared with standard treatment (docetaxel or pemetrexed) in HLA-A2 positive patients with locally advanced (IIIB) unsuitable for radiotherapy or metastatic Non-Small-Cell Lung Cancer.III
CA209-649"Estudio fase 3, aleatorizado, multicéntrico, abierto, de nivolumab más ipilimumab frente a oxaliplatino más fluoropirimidina en sujetos con cáncer gástrico o de la unión gastroesofágica, avanzado o metastásico, no tratado previamente"III
CO-338-043A Phase 3 Multicenter, Open-label, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.III
CA209-651Estudio fase III abierto, aleatorizado, de dos grupos, de nivolumab en combinación con ipilimumab frente a la combinación del estudio Extreme (cetuximab + cisplatino/carboplatino + fluorouracilo) como tratamiento de primera línea en el carcinoma de células escamosas de cabeza y cuello (CCECC) en recidiva o metastásico.III
BB608-303CRCA Phase III Study of BBI-608 in combination with 5- Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC).III
ARRAY-818-302A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs.
Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer.
III
PR-30-5017-CA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy.III
CA209-816Randomized, Open-Label Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC.III
AM0010-301A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen.III
MK3475-412Estudio de fase III, aleatorizado, de pembrolizumab administrado de forma concomitante con quimiorradioterapia y como tratamiento de mantenimiento frente a la quimiorradioterapia sola en pacientes con carcinoma epidermoide de cabeza y cuello localmente avanzado (KEYNOTE-412).III
WO39210ESTUDIO FASE III, DOBLE CIEGO, CONTROLADO CON PLACEBO, RANDOMIZADO Y MULTICÉNTRICO DE ATEZOLIZUMAB (ANTICUERPO ANTI-PD-L1) COMO TRATAMIENTO ADYUVANTE EN PACIENTES CON CARCINOMA DE CÉLULAS RENALES CON ALTO RIESGO DE DESARROLLO DE METÁSTASIS TRAS NEFRECTOMÍA.III
15-102-14Estudio En Fase III, Abierto, Aleatorizado y Multicéntrico de Nktr-102 Frente Al Tratamiento Elegido por El Médico En Pacientes Con Cáncer de Mama Metastásico que Tienen Metástasis Cerebrales Estables y Que Han Recibido Tratamiento con una Antraciclina, un Taxano y Capecitabina con Anterioridad.III
AFT-38Ensayo de fase III, aleatorizado y abierto para evaluar la eficacia y la seguridad de palbociclib + tratamiento anti-HER2 + tratamiento endocrino frente a tratamiento anti-HER2 + tratamiento endocrino tras el tratamiento de inducción para el cáncer de mama metastásico positivo para receptores hormonales (HR+)/positivo para HER2.III
AG120-C-005A Phase 3, Multicenter, Randomized, Double-Blind Study of AG-120 vs. Placebo in Previouslytreated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation.III
CA209-915A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma.III
E7080-G000-307A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR).III
B7461006“A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER”III
M16-298A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU).III
ARO 012A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects
with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA
Gene.
III
B9991016ESTUDIO EN FASE 3, ALEATORIZADO, DOBLE CIEGO SOBRE AVELUMAB COMBINADO CON LA QUIMIORRADIOTERAPIA DE REFERENCIA (CISPLATINO MÁS RADIOTERAPIA DEFINITIVA) EN COMPARACIÓN CON LA QUIMIORRADIOTERAPIA DE REFERENCIA EN EL TRATAMIENTO DE PRIMERA LÍNEA DE PACIENTES CON CARCINOMA EPIDERMOIDE LOCALMENTE AVANZADO DE CABEZA Y CUELLO.III
I3Y-MC-JPCFA Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus
Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer.
III
D0816C00014Estudio de Fase IIIb, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, del retratamiento con olaparib en pacientes con cáncer epitelial de ovario tratado previamente con un PARPi y con respuesta a la repetición de la quimioterapia con platino (OReO).III
CanStem111PEstudio en fase III de la combinación de BBI-608, nab-paclitaxel y gemcitabina en pacientes adultos con adenocarcinoma pancreático metastásico.III
CO39722ESTUDIO DE FASE III MULTICÉNTRICO, ABIERTO, RANDOMIZADO, CON DOS GRUPOS DE TRATAMIENTO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE COBIMETINIB EN COMBINACIÓN CON ATEZOLIZUMAB FRENTE A PEMBROLIZUMAB EN PACIENTES CON MELANOMA BRAFV600 TIPO SALVAJE AVANZADO, NO TRATADOS PREVIAMENTE.III
CA2099LAA Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC).III
D0816C00018LUCY - Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study. A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations.III
MK3475-598Estudio de fase 3, aleatorizado y doble ciego de pembrolizumab más ipilimumab en comparación con pembrolizumab más placebo en sujetos con cáncer de pulmón no microcítico con PD-L1 positivo (TPS ≥ 50 %), metastásico, en estadio IV y sin tratamiento previo (KEYNOTE-598).III
CO40016A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, TRIPLE-NEGATIVE BREAST CANCER OR HORMONE RECEPTOR– POSITIVE, HER2-NEGATIVE BREAST CANCER .III
CA209-722Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed.III
R2810-ONC-1676/GOG-3016 (CVP16 01)AN OPEN-LABEL, RANDOMIZED, PHASE 3 CLINICAL TRIAL OF REGN2810 VERSUS THERAPY OF NVESTIGATOR'S CHOICE CHEMOTHERAPY IN RECURRENT OR METASTATIC PLATINUMREFRACTORY CERVICAL CARCINOMA.III
CA2099ERA Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma.III
MO39193A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF ATEZOLIZUMAB PLUS CHEMOTHERAPY FOR PATIENTS WITH EARLY RELAPSING RECURRENT
(INOPERABLE LOCALLY ADVANCED OR METASTATIC) TRIPLE-NEGATIVE BREAST CANCER.
III
MK3475-689Estudio de fase III, aleatorizado y abierto para evaluar pembrolizumab
como tratamiento neoadyuvante y en combinación con la asistencia habitual como tratamiento adyuvante en el carcinoma epidermoide de cabeza y cuello locorregionalmente avanzado (CECC LA), extirpable, en estadio III-IVA.
III
GINECO-OV236bA randomized, double blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab.III
IMMU-132-05Estudio en fase III, internacional, multicéntrico, abierto, aleatorizado, de sacituzumab govitecan (IMMU-132) frente al tratamiento elegido por el médico en pacientes con cáncer de mama triple negativo metastásico que recibieron al menos dos tratamientos previos.III
ODO-TE-B301Estudio de fase III, aleatorizado, multicéntrico y multinacional de tesetaxel más una dosis reducida de capecitabina en comparación con capecitabina en monoterapia en pacientes con cáncer de mama metastásico o localmente avanzado, HER2 negativo y receptor hormonal positivo, tratado previamente con un taxano.III
KCP-330-020A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLEBLIND STUDY OF SELINEXOR (KPT-330) VERSUS
PLACEBO IN PATIENTS WITH ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS).
III
CL3-95005-006Estudio abierto, aleatorizado, fase 3 comparando trifluridina/tipiracilo (S95005) en combinación con bevacizumab y capecitabina en combinación con bevacizumab en primera línea de tratamiento de pacientes con cáncer colorrectal metastásico que no son candidatos a terapia intensiva (Estudio SOLSTICE).III
BGB-290-303Estudio de fase 3, en doble ciego y aleatorizado, de BGB-290 frente a placebo como tratamiento de mantenimiento en pacientes con cáncer gástrico localmente avanzado o metastásico, inoperable, que han respondido a una quimioterapia de primera línea basada en el platino.III
BGB-A317-301A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma.III
GO40241A PHASE III, DOUBLE-BLINDED, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM-BASED
CHEMOTHERAPY IN PATIENTS WITH RESECTABLE STAGE II, IIIA, OR SELECT IIIB NON−SMALL CELL LUNG CANCER.
III
D0816C00020OPINIÓN - Estudio en fase IIIb, abierto, de grupo único y multicéntrico de la monoterapia de mantenimiento con olaparib en pacientes con cáncer de ovario recidivante sin mutación de BRCA en línea germinal y sensible al platino que están en respuesta parcial o completa tras la quimioterapia con platino.III
EF-27PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma.III
BGB-A317-302Estudio de Fase 3, aleatorizado, controlado, abierto y global, comparativo de la eficacia de BGB-A317, un anticuerpo anti-PD-1, frente a quimioterapia como segunda línea de tratamiento en pacientes con carcinoma esofágico epidermoide avanzado no resecable/metastásico.III
BLU-285-1303An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST).III
BO40336ESTUDIO DE FASE III, ABIERTO Y ALEATORIZADO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE ALECTINIB ADYUVANTE FRENTE A LA QUIMIOTERAPIA ADYUVANTE CON UN DERIVADO DEL PLATINO EN PACIENTES CON CARCINOMA DE PULMÓN NO MICROCÍTICO POSITIVO PARA LA CINASA DEL LINFOMA ANAPLÁSICO EN ESTADIO IB (TUMORES ≥ 4 CM) A IIIA COMPLETAMENTE EXTIRPADO.III
PP06489A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5-FU/FA and
Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in the adjuvant treatment of patients with Stage III or high-risk Stage II colorectal cancer.
III
PP06490Estudio de fase III, doble ciego, multicéntrico, controlado con placebo de PledOx usado junto con FOLFOX6 modificado (5 FU/FA y oxaliplatino) para prevenir la neuropatía periférica inducida por quimioterapia (NPIQ) en pacientes con cáncer colorrectal metastásico en tratamiento de primera línea.III
MK3475-789Estudio de fase 3, aleatorizado y doble ciego de quimioterapia con pemetrexed + platino con o sin pembrolizumab (MK-3475) en pacientes con cáncer de pulmón no microcítico (CPNM) no epidermoide, metastásico, con mutación de EGFR y resistente a inhibidores de la tirosina cinasa (KEYNOTE-789).III
8951-CL-0301Estudio de fase 3 internacional, multicéntrico, doble ciego y aleatorizado, de la eficacia de IMAB362 más mFOLFOX6, en comparación con placebo más mFOLFOX6, como tratamiento de primera línea en sujetos con adenocarcinoma gástrico o de la unión gastroesofágica localmente avanzado irresecable o metastásico, claudin (CLDN)18.2 positivo y HER2 negativo.III
MK3475-756A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer (KEYNOTE-756) .III
MK3475-716Tratamiento adyuvante con pembrolizumab frente a un placebo en el melanoma en estadio II de alto riesgo resecado: estudio de fase 3, doble ciego y aleatorizado (KEYNOTE 716).III
MK3475-811Ensayo de fase III, aleatorizado y doble ciego para comparar trastuzumab más quimioterapia y pembrolizumab con trastuzumab más quimioterapia y placebo como tratamiento de primera línea en participantes con adenocarcinoma gástrico o de la unión gastroesofágica avanzado con HER2 positivo (KEYNOTE 811).III
C3441021Estudio en Fase III, Aleatorizado, Doble Ciego, Controlado con Placebo de Talazoparib con Enzalutamida en el Cáncer de Próstata Metastásico Resistente a la castración.III
Brigatinib-3001Estudio en fase III, aleatorizado y abierto de brigatinib (ALUNBRIGTM) en comparación con alectinib (ALECENSA®) en pacientes con cáncer de pulmón no microcítico avanzado positivo para cinasa de linfoma anaplásico que han progresado con crizotinib (XALKORI®)III
MK3475-859A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE-859).III
ENGOT-Cx10/GEICO 68-C/ BEAT ccA Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix.III
GRASPANC-2018-01A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma.III
CA045001/18-214-08A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma.III
2125-MEL-301A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma.III
D933QC00001A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC).III
MK3475-913A Phase 3 Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) as First-line Therapy in Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-913).III
D933SC00001Ensayo fase III, aleatorizado, abierto, controlado, multicéntrico, internacional de durvalumab en combinación con el tratamiento estándar con quimioterapia y durvalumab en combinación con tremelimumab y el tratamiento estándar con quimioterapia frente al tratamiento estándar con quimioterapia solo, en primera línea en pacientes con cáncer urotelial localmente avanzado irresecable o metastásico.III
CACZ885U2301A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab
plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1).
III
CO-338-087ATHENA (A Multicenter, Randomized, Double-Blind, PlaceboControlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy).III
1333-GUCGA Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.III
DS8201-A-U302A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.III
ENGOT OV41A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months.III
TTD-18-01Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in ntreated patients with wild-type RAS metastatic, primary left-sided, unresectable colorectal cancer: The CRSEQUENCE.III
MK3475-630Estudio de fase III, aleatorizado, doble ciego y controlado con placebo para evaluar pembrolizumab frente a un placebo como tratamiento adyuvante después de cirugía y radioterapia del carcinoma epidermoide cutáneo localmente avanzado (CEC LA) de alto riesgo, MK3475-630.III
ETOP13-18Ensayo clínico Fase III multicéntrico aleatorizado que compara atezolizumab más bevacizumab y la quimioterapia habitual con bevacizumab y la quimioterapia habitual como tratamiento de primera línea para el mesotelioma pleural maligno.III
BO40747A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH NEOADJUVANT DOXORUBICIN+ CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL+ TRASTUZUMAB+ PERTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER.III
ISO-CC-007A randomized, multicenter, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer.III
MK7902-008A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and immunotherapy (anti-PD-1/PD-L1 inhibitor) (LEAP-008).III
XL184–311A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy.III
DCC-2618-03-002A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib.III
7465-CL-0301An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301).III
BGB-A317-306Estudio de fase 3, aleatorizado, controlado con placebo y en doble ciego, para evaluar la eficacia y la seguridad de tislelizumab (BGB-A317) en combinación con quimioterapia como tratamiento de primera línea en pacientes con carcinoma esofágico epidermoide recurrente localmente avanzado o metastásico, no resecable.III
BGOG-EN5/ENGOT-EN5/SIENDOAn Investigator-Sponsored Randomized Phase III Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer.III
D933RC00001A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA).III
MK7902-011/E7080-G000-317A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally dvanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011).III
MK7339-010Estudio de fase 3, aleatorizado y abierto de pembrolizumab (MK-3475) más olaparib frente a acetato de abiraterona o enzalutamida en participantes con cáncer de próstata resistente a la castración metastásico (CPRCm) que no son seleccionados por defectos en la reparación por recombinación homóloga y que han mostrado fracaso con el tratamiento previo con un fármaco hormonal de última generación (FHUG) y quimioterapia (KEYLYNK-010).III
IRFMN-EN-7556PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO CONTROLLED TRIAL OF ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN WOMEN WITH ADVANCED/RECURRENT ENDOMETRIAL CANCER.III
MK3475-867A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non
Small Cell Lung Cancer (NSCLC) (KEYNOTE-867).
III
INCB 54828-302A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302).III
CA209-8Y8A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors.III
DS8201-A-U303Estudio en fase III, multicéntrico, aleatorizado, abierto y controlado con principio activo de DS-8201a, un conjugado de fármaco y anticuerpo (CAF) anti-HER2, en comparación con el tratamiento elegido por el médico en sujetos con cáncer de mama irresecable o metastásico (o ambos) con expresión baja de HER-2.III
D081SC00001Ensayo en fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo de olaparib y abiraterona en comparación con placebo y abiraterona como tratamiento de primera línea en varones con cáncer de próstata metastásico resistente a la castración.III
D3614C00001DB, Rando study assigned the efficacy and Safety of Capivasertib+pacli VS placebo+pacli as 1L for pa with histologically confirmed , locally advanced (inoparable)or M1 TNBC.III
POL6326-009An International, Phase 3, Multicenter, Randomized, Open-Label Trial Comparing Balixafortide in combination with Eribulin versus Eribulin alone in Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer.III
CLEE011O12301CCLEE011O12301CIII
ITM-LET-01A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somato-statin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).III
MS200647-0005A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancer.III
CA209-8HWA Phase 3b Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer.III
IBCSG 59-19 / BIG 18-02A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer.III
IMMU-132-09Phase 3 Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with
Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast
Cancer (MBC) who have failed at least two prior chemotherapy regimens.
III
CO41101A PHASE IB/III STUDY OF IPATASERTIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS
PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN HORMONE RECEPTOR POSITIVE AND HER2 NEGATIVE LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER.
III
XL184–313A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab
versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of
Intermediate or Poor Risk.
III
R2810-ONC-1788A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma.III
MK3475-966A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma.III
MM-398-01-03-04-IIIRESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy. III
OZM-061Olala: A Retrospective/Prospective Analysis of Characterization of the Long-term Responders on Olaparib in Solid Tumours.IV
GEICO1703Incidence of Somatic and Germline BRCA Mutations in a Spanish Large Clinic-Based Cohort of Patients with non-Mucinous Epithelial Ovarian Cancer with Cross-Laboratory Validation of Somatic Technique (BoRNEO) – A GEICO Study.IV
GEIS 43RETROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH METASTATIC, UNRESECTABLE OR LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMOURS (GIST) TREATED WITH SUNITINIB. EXPLORATORY ANALYSIS OF PROGNOSTIC AND PREDICTIVE FACTORS IN LONG-TERM RESPONDER PATIENTS.IV
GEIS 45"Determinantes clínicos y moleculares de respuesta y progresión a la inhibición de KIT en pacientes con tumores del estroma gastrointestinal (GIST) con respuesta prolongada a Imatinib".IV
GEIS 44Identificacion de biomarcadores pronósticos en el osteosarcoma de alto grado.IV
ISG-GEIS-OS-2Estudio prospectivo observacional de la expresión de ABCB1/P-glicoproteína como factor para la estratificación biológica del osteosarcoma no metastático de las extremidades.IV
INN-PAC-2017-01Estudio Observacional Retrospectivo para Identificar Biomarcadores Predictivos de Respuesta a Paclitaxel en Pacientes con Cáncer de Mama Metastásico.IV
IBCSG 48-14/ BIG 8-13IBCSG 48-14/ BIG 8-13IV
BAY 88-8223/16996A Phase 4 long-term follow-up study to define the safety profile of radium-223 dichloride.IV
SOGUG-2019-01Estudio observacional y retrospectivo, sobre el valor pronóstico de la expresión de PDL1 y otros marcadores moleculares angiogénicos, en pacientes con carcinoma de células renales (CCR) avanzado o metastásico tratados con fármacos antiangiogénicos en primera línea.IV
PFI-ITK-2015-01/ A6181 218"Estudio observacional, prospectivo y multicéntrico de calidad de vida en relación con la fatiga y el síndrome mano-pie de los pacientes con carcinoma renal metastásico tratados con un inhibidor de la tirosina quinasa en primera línea (Estudio TROYA)".IV
F-FR-60000-001Prospective noninterventional study of cabozantinib tablets in adults with advanced renal cell carcinoma following prior vascularendothelial growth factor (VEGF)-targeted therapy.IV
A4061089/PFI-AXI-2017 -01"Análisis retrospectivo de factores clínicos asociados a un mayor beneficio con Axitinib en Cáncer Renal metastásico".IV
CPDR001X2X01BAn open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who
have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments.
IV
20180293A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in   Subjects with Gastric Cancer.IV
40KA98 UVEAUse Via Expanded Access to Brigatinib.IV
ML40221REAL WORLD CLINICAL PRACTICE STUDY TO EVALUATE 2ND LINE TREATMENT DECISION MAKING AS PER STANDARD OF CARE AND BASED ON FOUNDATION MEDICINE® IN PATIENTS WITH LOCALLY ADVANCED OR
METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH ADENOCARCINOMA HISTOLOGY IN SPAINREAL WORLD CLINICAL PRACTICE STUDY TO EVALUATE 2ND LINE TREATMENT DECISION MAKING AS PER STANDARD OF CARE AND BASED ON FOUNDATION MEDICINE® IN PATIENTS WITH LOCALLY ADVANCED OR
METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH ADENOCARCINOMA HISTOLOGY IN SPAIN.
IV
BO39633ESTUDIO DE EXTENSIÓN MULTICÉNTRICO, ABIERTO EN PACIENTES INCLUIDOS PREVIAMENTE EN UN ESTUDIO CLÍNICO DE ATEZOLIZUMAB PROMOCIONADO POR GENENTECH Y/O F. HOFFMANN-LA ROCHE LTD.IV
MK3475-587A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.IV
GEICAM 2016-04AN OBSERVATIONAL, RETROSPECTIVE STUDY ON THE PROGRESS OF BREAST CANCER CASES IN MALES AND THE ASSESSMENT OF RELAPSE RISK THROUGH GENE SEQUENCING.IV
ROC-MMT-2017-01/ML 40004OBSERVATIONAL CROSS-SECTIONAL STUDY EVALUATING THE SOCIODEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS WITH METASTATIC MELANOMA HARBORING A BRAF V600 MUTATION TREATED WITH COBIMETINIB AND VEMURAFENIB BASED ON ROUTINE CLINICAL PRACTICE.IV
GEM-1801/GEM-IPI-201 8-01ESTUDIO OBSERVACIONAL DESCRIPTIVO SOBRE LAS CARACTERÍSTICAS DEL MELANOMA AVANZADO Y METASTÁSICO EN ESPAÑA.IV
D4200C00104Estudio europeo observacional y prospectivo para evaluar el beneficio/riesgo de vandetanib (CAPRELSA™) 300 mg en
pacientes con cáncer medular de tiroides (CMT) sintomático, agresivo, esporádico, localmente avanzado o metastásico, no
resecable, con o sin mutación del RET.
IV
IPS-LAN-2018-01“Efectividad de la dosis de 120 mg de lanreotida en pacientes con tumores neuroendocrinos pancreáticos (TNEP) localmente avanzados o metastásicos en la práctica clínica habitual”IV
VHIO18001Identificación de los diferentes patrones de captación mediante PET con 18F-FDG y 68Ga-DOTApéptidos en los tumores neuroendocrinos avanzados.IV
IRONMAN-ES"IRONMAN-ES: Estudio prospectivo observacional de parámetros clinicos y biomarcadores en cáncer de próstata avanzado en hospitales de España".IV
C13-1Follow-up to the AVANT study up to 8 and 10 years (median follow-up) in patients with colon carcinoma.IV
FAMOSAEstudio multicéntrico abierto para la evaluación de la frecuencia de mutaciones en genes accionables asociados al Cáncer Hereditario.IV
BIG 14-01AURORA: Investigación de las alteraciones moleculares en el cáncer de mama metastásico.IV
PUMA-NER-9501HER-Seq: A Blood-based Screening Study to Identify Patients with HER2 Mutations for Enrollment into Clinical Research Studies of Neratinib.IV
ML40677ESTUDIO OBSERVACIONAL PARA LA RECOGIDA DE LA SUPERVIVENCIA GLOBAL DE LOS PACIENTES INCLUIDOS EN EL ESTUDIO NEOHX (ML25189).IV
ART-CAB-2013-01Efficacy of Cabazitaxel, Abiraterone and doceTaxel Sequence in men with metastatic castration-resistant prostate cancer: a European, retrospective, observational study (CATS).IV
CNIO-CP-02-2014Estudio prospectivo multicéntrico de factores pronósticos en cáncer dePRÓStata resistente a la castración tratados con doceTaxel o CabazitaxelIV
SOG-PLA-2016-01Estudio prospectivo de la utilidad de la biopsia líquida como factor predictor y pronóstico en pacientes con carcinoma urotelial metastásico en progresión tras quimioterapia basada en platino. IV

Early Clinical Drug Development

Code Clinical Trial Title Phase
MM-398-01-03-04 RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy. I
2SMALL Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-Based Chemotherapy. I
CA209-358 Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab.
(BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors
I
D419NC00001 Estudio de fase I de durvalumab e IPH2201 en pacientes adultos con tumores sólidos avanzados seleccionados. I
4010-01-001 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors. I
WO39409 A phase Ib combination study of rucaparib (CO-338) and atezolizumab (MPDL3280A) in patients with advanced gynecologic cancers and triple-negative breast cancer. I
BGB-290-103 A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors. I
YO40482 A PHASE Ib STUDY OF COBIMETINIB ADMINISTERED IN COMBINATION WITH NIRAPARIB, WITH OR WITHOUT ATEZOLIZUMAB, TO PATIENTS WITH ADVANCED PLATINUM-SENSITIVE OVARIAN CANCER. I
0402 A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in
Combination with Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin, in Adults with Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer.
I
3113001 Seguridad y tolerabilidad de dosis únicas y repetidas de ODM-203: primer estudio en el ser humano, abierto, no aleatorizado, multicéntrico, no controlado y con aumento progresivo de la dosis en pacientes con tumores sólidos avanzados. I
AMC303-01 A safety, tolerability and pharmacokinetic dose escalation and expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin? I
MK7339-002 Estudio de fase 2 de olaparib en monoterapia en participantes con cáncer avanzado positivo para la mutación del sistema de reparación por recombinación homóloga (HRRm) o déficit del sistema de recombinación homóloga (DRH) tratados previamente. Basket  
SGNTV-001 Estudio de fase 2, abierto, de tisotumab vedotina en tumores sólidos con enfermedad localmente avanzada o metastásica. Basket  
Debio 1143-106 SMARTPLUS-106: Debio 1143 a SMAC Mimetic In Combination With Nivolumab In Patients Failing Prior PD-1/PD-L1 Treatment: A Basket Trial. A dose-optimization, exploratory phase Ib/II study to assess safety and efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) mimetic Debio 1143, when given in combination with the anti-PD-1 antibody nivolumab in patients with specific solid tumors who have progressed during or immediately after anti-PD-1/PD-L1 treatment. Basket  
BLU-285-1101 A Phase 1 Study of BLU-285 in Patients with Gastrointestinal Stromal Tumors (GIST) and other Relapsed and Refractory Solid Tumors. I
TRASTS Ensayo clinico Fase I-II, abierto, prospectivo y muticéntrico, que explora la combinación de Trabectedina y Radioterapia en pacientes con Sarcoma de tejidos Blandos. I
INCB 59872-103 An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma. I
GEIS 58 OLATRASTS Ensayo clínico de fase I con Olaratumab más Trabectedina en pacientes con sarcoma de tejidos blandos avanzado. I
GO39374 A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY EVALUATING THE SAFETY, TOLERABILITY, AND
PHARMACOKINETICS OF GDC-0077 AS A SINGLE AGENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE AND TARGETED THERAPIES IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT HORMONE-RECEPTOR POSITIVE BREAST CANCER.
I
C0541001 A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06804103 IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) POSITIVE SOLID TUMORS. I
MEN1611-01 Estudio abierto, multicéntrico, de fase Ib, de escalado de dosis, de MEN1611, un inhibidor de PI3K combinado con trastuzumab ± fulvestrant, en sujetos con cáncer de mama irresecable y localmente recurrente (avanzado) o metastásico (a/m) HER2 positivo con mutación PIK3CA que ha progresado con un tratamiento basado en anti-HER2. I
PUMA NER-5201 An Open-Label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal
Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR gene amplification.
I
BP39365 ESTUDIO DE FASE IB MULTICÉNTRICO, ABIERTO, RANDOMIZADO, DE ESCALADA DE DOSIS PARA EVALUAR LA SEGURIDAD, FARMACOCINÉTICA Y ACTIVIDAD TERAPÉUTICA DE RO6874281 EN COMBINACIÓN CON ATEZOLIZUMAB ± BEVACIZUMAB, TRAS TRATAMIENTO PREVIO CON OBINUTUZUMAB, EN PACIENTES CON CARCINOMA DE CÉLULAS RENALES AVANZADO Y/O METASTÁSICO NO RESECABLE. I
B9991023 A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES. I
INCMGA0012-203 A Phase 2 Study of INCMGA00012 (PD-1 inhibitor) in Participants With Selected Solid Tumors (PODIUM-203). Basket  
CLXH254X2101 Estudio fase I, de búsqueda de dosis de LXH254 oral en pacientes adultos con tumores sólidos avanzados portadores de alteraciones en la vía de señalización MAPK. I
ARRAY-162-202 An Open-label Phase 1b/2 Study of Binimetinib Administered in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Patients with Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer with RAS Mutation I
GEMCAD 1602 A single arm Phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated mismatch
repair-proficient (MSS) metastatic colorectal cancer patients.
I
M15-913 An Open Label Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies. I
MK3475-158 Ensayo clínico de evaluación de biomarcadores predictivos con pembrolizumab (MK-3475) en pacientes con tumores sólidos avanzados (KEYNOTE 158). Basket  
PRN1371-001 A Phase 1 Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR1-4 Kinase Inhibitor, in Adult Patients with
Advanced Solid Tumors, followed by an Expansion Cohort in Patients with FGFR1, 2, 3, or 4 Genetic Alterations.
I
GO30103 A PHASE Ia/Ib OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MTIG7192A AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS. I
MK4280-001 A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors. I
PM14-A-001-17 Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors. I
KO-ERK-001 Un primer ensayo en humanos de fase I de KO-947 en malignidades no hematológicas
localmente avanzadas, no reseccionableso metastásicas
recidivantes y/o refractarias.
I
CP-MGA012-01 A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors. I
5225101 A Phase Ib Study to Evaluate the Safety, Tolerability and Efficacy of Gatipotuzumab and Tomuzotuximab Combination in Patients with EGFR-Positive Metastatic Solid Tumors. I
W00101-IV-1-01 Estudio abierto en fase I/II de aumento escalonado de la dosis y ampliación de la dosis de una infusión intravenosa de W0101, un conjugado anticuerpo-fármaco, en pacientes con tumores sólidos avanzados o metastásicos.
Estudio abierto, multicéntrico, internacional.
I
CB103-C-101 A PHASE I/IIA, MULTI-CENTRE, OPEN-LABEL, DOSE-ESCALATION STUDY WITH EXPANSION ARMS TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CB-103 ADMINISTERED ORALLY IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMOURS AND HAEMATOLOGICAL  ALIGNANCIES CHARACTERISED BY ALTERATIONS OF THE NOTCH SIGNALLING PATHWAY . I
MEN1309-01 OPEN-LABEL, MULTICENTER, PHASE I DOSE ESCALATION STUDY OF MEN1309, A CD205 ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH CD205-POSITIVE METASTATIC SOLID TUMORS AND NON-HODGKIN LYMPHOMA. I
CLHC165X2101 A Phase I/Ib, open-label, multi-center dose-escalation and dose-expansion study of the safety and tolerability of intratumorally administered LHC165 single agent and in combination with PDR001 in patients with advanced malignancies. I
BLU-667-1101 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors. I
BGB-A317/BGB-290 Estudio en fase I/Ib, abierto, de dosis múltiples, con aumento y ampliación de la dosis para investigar la seguridad, la farmacocinética y la actividad antitumoral del anticuerpo monoclonal anti-PD-1 BGB-A317 en combinación con el inhibidor de la PARP BGB-290 en sujetos con tumores sólidos en estadio avanzado I
SRA737-02 Ensayo en fase I/II de SRA737 (un inhibidor de Chk1) administrado por vía oral en combinación con gemcitabina más cisplatino o gemcitabina únicamente en pacientes con cáncer avanzado. I
AG270-C-001 Estudio Fase I de AG-270 en el tratamiento de sujetos con tumores sólidos avanzados o linfoma con deleción homocigótica de MTAP. I
MSC-1-101 A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MSC-1 in Patients with Advanced Solid Tumors. I
CA022-001 Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors. I
LOXO-EXT-17005 Estudio en fase I/II del inhibidor de la actividad de la TRK LOXO-195 en pacientes adultos y pediátricos que padezcan un cáncer portador de genes de fusión NTRK tratado previamente. I
LOXO-RET-17001 A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medularry Thyroid Cancer, and Other Tunors with Increased RET Activity. I
GCT1029-01 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1029 in patients with malignant solid tumors. I
204686 A Phase I, Open-Label Study of GSK1795091 Administered in Combination with Immunotherapies in Participants with Advanced Solid Tumors. I
J1F-MC-JZFA A Phase 1a/1b Study of LY3405105 Administered to Patients with Advanced Solid Tumors. I
C2321001 ESTUDIO DE FASE I DE AUMENTO GRADUAL DE LA DOSIS Y DE COHORTES EXPANDIDO DE PF-06821497 EN EL TRATAMIENTO DE PACIENTES ADULTOS CON CÁNCER DE PULMÓN MICROCÍTICO (CPM) RECIDIVANTE O RESISTENTE, CÁNCER DE PRÓSTATA RESISTENTE A LA CASTRACIÓN (CPRC) Y LINFOMA FOLICULAR (LF). I
ACT15377 Estudio en fase 1/2, abierto, multicéntrico, para evaluar la seguridad, eficacia preliminar y farmacocinética de isatuximab (SAR650984) en combinación con atezolizumab o solo isatuximab en pacientes con enfermedades malignas avanzadas. I
INCB 01158-101 Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (formerly known as CB-1158) as a Single Agent and in Combination with Immune Checkpoint Therapy in Patients with vanced/Metastatic Solid Tumors. I
2102-ONC-102 A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation. I
ICO-VCN-H&N-2018 A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination With Durvalumab (MEDI4736) in Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck. I
GCT1046-01 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects
with malignant solid tumors.
I
20140318 Estudio de fase 1b/2 multicéntrico y abierto para evaluar la seguridad de talimogene laherparepvec inyectado en tumores hepáticos en monoterapia o combinado con pembrolizumab sistémico (MASTERKEY-318). I
8374-CL-0101 A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors. I
NBTXR3/102 ESTUDIO DE FASE I DE AUMENTO ESCALONADO/AMPLIACIÓN DE LA DOSIS DE NBTXR3 ACTIVADO MEDIANTE RADIOTERAPIA DE INTENSIDAD MODULADA EN PACIENTES CON CARCINOMA DE CÉLULAS ESCAMOSAS LOCALMENTE AVANZADO EN LA CAVIDAD BUCAL O LA OROFARINGE. I
SC103 A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors. I
CTNO155B12101 A Phase Ib, open-label, multi-center study to characterize the safety, tolerability, and preliminary efficacy of TNO155
in combination with spartalizumab or ribociclib in selected malignancies.
I
NP41300 AN OPEN LABEL, MULTICENTER, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE SAFETY/TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PRELIMINARY ANTI TUMOR ACTIVITY OF RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
SL01-DEL-101 Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects with Advanced Solid Tumors or Lymphomas. I
LOXO-TRK-15002 A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors. Basket  
RXDX-101-02 An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements. Basket  
INCAGN1876-201 Estudio de fase I/II sobre la seguridad, la tolerabilidad y la eficacia de INCAGN01876 en combinación con inmunoterapias en sujetos con neoplasias malignas avanzadas o metastásicas. Basket  
CNIR178X2201 Estudio fase 2, multicéntrico, abierto, de NIR178 en combinación con PDR001, en pacientes con tumores sólidos avanzados seleccionados y linfoma no Hodgkin. Basket  
CA209-848 A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H). Basket  
Debio1347-201 Ensayo "basket" de fase II del paninhibidor del FGFR selectivo por vía oral Debio 1347 en pacientes con tumores sólidos que presentan una fusión de FGFR1, FGFR2 o FGFR3. Basket  
EMR200647-001 Ensayo de fase I, abierto, con dosis múltiples ascendentes, para investigar la seguridad, tolerabilidad, farmacocinética, y actividad biológica y clínica de MSB0011359C en sujetos con tumores sólidos metastásicos o localmente avanzados y expansión a indicaciones seleccionadas. I
63723283LUC1001 Estudio de primera administración en humanos, abierto, Fase 1/2 para evaluar la seguridad, farmacocinética, farmacodinámica y la actividad clínica de JNJ-63723283, un anticuerpo monoclonal Anti-PD1 en sujetos con cáncer avanzado. I
WIN001 Survival Prolongation by Rationale INnovative Genomics (SPRING): A proof of concept study to explore safety and efficacy of tri-therapy approach in advanced/metastatic NSCLC and retrospectively assess the ability of integrated genomics and transcriptomics to match patients to the combination. I
SYM015-01 Ensayo de fase 1a/2a, abierto y multicéntrico, para investigar la seguridad, tolerabilidad y actividad antitumoral de dosis repetidas de Sym015, una mezcla de anticuerpos monoclonales dirigida frente al receptor MET, en pacientes con tumores malignos sólidos en fase avanzada. I
CPDR001C2101 Phase Ib, multicenter, open label study of PDR001 in combination with platinum-doublet chemotherapy in PD-L1unselected, metastatic NSCLC patients. I
BO39610 ESTUDIO EN PARAGUAS DE FASE Ib/II, SIN ENMASCARAMIENTO, MULTICÉNTRICO Y ALEATORIZADO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE COMBINACIONES DE TRATAMIENTOS BASADOS EN MÚLTIPLES INMUNOTERAPIAS EN PACIENTES CON CARCINOMA DE PULMÓN NO MICROCÍTICO METASTÁSICO (MORPHEUS PULMONAR). I
IO102-012 Estudio en fase I/II, abierto, aleatorizado para investigar la seguridad y la eficacia de IO102 en combinación con pembrolizumab, con o sin quimioterapia, como tratamiento de primera línea para pacientes con cáncer de pulmón no microcítico metastásico. I
Brigatinib-1001 A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors. I
BP40657 ESTUDIO FASE IB/II DE DOS PARTES PARA INVESTIGAR LA FARMACOCINÉTICA, EFICACIA Y SEGURIDAD DEL ATEZOLIZUMAB SUBCUTÁNEO EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO ESTADIO IV. I
AC00102014-101 Estudio en fase I, multicéntrico y abierto de seguridad, farmacocinética y eficacia preliminar del inhibidor del EGFR que evita el gen natural, AC0010MA (abivertinib maleate), en pacientes adultos con cáncer de pulmón no microcítico (CPNM) con EGFRmut y la mutación adquirida T790M previamente tratado. I
61186372EDI1001 A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer. I
D7980C00001 A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics
Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects with Advanced Solid Tumors.
I
XL184-021 (PULMON) A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors. I
CLXH254X2102 A Phase Ib, open-label, multicenter study of oral LXH254- centric combinations in adult patients with advanced or
metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer or NRAS mutant melanoma.
I
73841937NSC2001 A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients with EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC). I
CA223-001 A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors. Basket  
BP40234 AN OPEN-LABEL, MULTICENTER, PHASE II STUDY TO EVALUATE THE THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE, CONSISTING OF INTERLEUKIN-2 VARIANT (IL-2V) TARGETING FIBROBLAST ACTIVATION PROTEIN-Α (FAP), IN COMBINATION WITH ATEZOLIZUMAB (ANTI-PD-L1), ADMINISTERED INTRAVENOUSLY, IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. Basket  
BP41054 AN OPEN-LABEL, MULTICENTER, PHASE IB STUDY TO EVALUATE SAFETY AND THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE, CONSISTING OF INTERLEUKIN-2 VARIANT (IL-2V) TARGETING FIBROBLAST ACTIVATION PROTEIN-Α (FAP), IN COMBINATION WITH PEMBROLIZUMAB (ANTI-PD-1), IN PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED AND/OR METASTATIC MELANOMA. I
MK3475-555 Estudio clínico de fase 1 aleatorizado de pembrolizumab (MK-3475) para evaluar la biodisponibilidad relativa de la inyección subcutánea frente a la infusión intravenosa en participantes con melanoma avanzado (KEYNOTE-555). I
NP40435 AN OPEN LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION, PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ANTI TUMOR ACTIVITY OF RO7121661, A PD-1/TIM-3 BISPECIFIC  NTIBODY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
IOV-COM-202 A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors. Basket  
CLGK974X2101 ESTUDIO FASE I, ABIERTO, DE ESCALADA DE DOSIS DE LGK974 ORAL, EN PACIENTES CON ENFERMEDADES MALIGNAS DEPENDIENTES DE LIGANDOS DE WNT2 I
CL1-95005-001 Estudio de fase I de escalada de dosis con S 95005 (TAS-102) en combinación con oxaliplatino (TAS-OX) en cáncer colorrectal metastásico. I
1401-0001 An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 905677 administered intravenously in patients with advanced solid tumours. I
MCLA-158-CL01 Phase 1 dose escalation and cohort expansion study evaluating single-agent MCLA-158 in metastatic colorectal cancer and other advanced solid tumors. I
CPDR001X2102 "Estudio de fase Ib, multicéntrico, abierto para determinar la seguridad, tolerabilidad y farmacodinámica (PD) de PDR001 en
combinación con LCL161, everolimus (RAD001) o panobinostat (LBH589)".
I
BAY 1163877/19774 A multicenter Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and recommended Phase 2 dose (RP2D)of the combination of rogaratinib and copanlisib in patients with FGFR-positive refractory, locally advanced or metastatic solid tumors. I
CP-MGD013-01 A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms. I
INCB 54828-207 A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207). Basket  
CC-90010-ST-001 A PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-90010 IN SUBJECTS WITH ADVANCED SOLID TUMORS AND RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMAS. I
3121001 Safety and pharmacokinetics of ODM-207 in patients with selected advanced solid tumours: an open-label, non-randomised, uncontrolled, multicentre, first-in-human study. I
CTNO155X2101 An open-label, multi-center, phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumors. I
64619178EDI1001 Estudio de primera administración en humanos, fase I, abierto, sobre la seguridad, farmacocinética y farmacodinamia de JNJ-64619178, un inhibidor de la proteína arginina-metiltransferasa-5 (PRMT5) en pacientes con cánceres avanzados. I
KO-TIP-001 An Open Label Phase II Study of Tipifarnib in Advanced NonHematological Malignancies with HRAS Mutations. Basket  
VHIO17002 Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours. Basket  
CC-90011-ST-001 A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-90011 IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN’S LYMPHOMAS. I
D2615C00001 An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY). I
204697 Estudio de fase IB, abierto, de aumento escalonado y expansión de la dosis, para investigar la seguridad, la farmacocinética, la farmacodinámica y la actividad clínica de GSK525762 en combinación con tratamiento de privación androgénica y otros agentes en sujetos con cáncer de próstata resistente a la castración (CRPC). I
64091742PCR2002 Estudio fase 1b-2 de Niraparib en combinación con terapias para el tratamiento del cáncer de próstata metastásico resistente a castración. I
56021927PCR2032 Estudio de fase Ib, abierto y multicéntrico de JNJ-63723283, un inhibidor de PD-1 administrado en combinación con apalutamida a pacientes con cáncer de próstata metastásico resistente a la castración I
A206T-G01-001 A Phase 1/2 open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligand therapy in patients with prostate specific membrane antigen (PSMA) positive (68Ga-PSMA-R2) progressive metastatic castration-resistant prostate cancer, following previous systemic
treatment.
I
BO40933 A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF IPATASERTIB IN COMBINATION WITH RUCAPARIB IN PATIENTS WITH ADVANCED BREAST, OVARIAN, OR PROSTATE CANCER. I
D6500C00001 A Phase I, Open-Label Study to Assess the Safety, Tolerability,Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD0156 Monotherapy or in Combination with either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients with Advanced Malignancies. I
D4620C00001 A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients with Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTENdeficient/ mutated or PIK3CB mutated/amplified Advanced Solid Malignancies, with Expansion to Assess the Pharmacodynamic Activity of AZD8186. I
CA012-004 Estudio fase 1/2a de BMS-986178 administrado en monoterapia y en combinación con nivolumab o ipilimumab en tumores sólidos avanzados. I
DEBIO 1347-101 A phase I, gene alteration-based, open label, multicenter study of oral Debio1347 (CH5183284) in patients with advanced solid malignancies, whose tumours have an alteration of the FGFR 1, 2 or 3 genes. I
TPU-TAS-120-101 A DOSE-FINDING PHASE 1 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS WITH OR WITHOUT FIBROBLAST GROWTH FACTOR/RECEPTOR (FGF/FGFR)-RELATED ABNORMALITIES FOLLOWED BY A PHASE 2 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS OR MULTIPLE MYELOMA WITH FGF/FGFR-RELATED ABNORMALITIES. I
TED13751 Estudio de primera administración en humanos para evaluar la seguridad, farmacocinética y actividad antitumoral de SAR408701 en pacientes con tumores sólidos avanzados. I
PCYC-1128-CA A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors. I
CO39083 A PHASE IB OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND PHARMACOKINETICS
OF COBIMETINIB IN COMBINATION WITH BEVACIZUMAB AND IMMUNOTHERAPY WHEN ADMINISTERED IN PATIENTS WITH GASTROINTESTINAL AND OTHER TUMORS.
I
GO39733 A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS. I
BP40087 ESTUDIO DE FASE IA/IB, ABIERTO, MULTICÉNTRICO, DE ESCALADA DE DOSIS, PARA EVALUAR LA SEGURIDAD, LA FARMACOCINÉTICA Y LA ACTIVIDAD ANTITUMORAL PRELIMINAR DE RO7122290, UN LIGANDO 4-1BB (CD137L) DIRIGIDO CONTRA LA PROTEÍNA α DE ACTIVACIÓN DE FIBROBLASTOS (FAP), CON O SIN PRETRATAMIENTO CON OBINUTUZUMAB, EN PACIENTES CON TUMORES SÓLIDOS AVANZADOS Y/O METASTÁSICOS, EN MONOTERAPIA O EN COMBINACIÓN CON ATEZOLIZUMAB, SEGUIDO DE COHORTE(S) DE EXPANSIÓN ESPECÍFICA(S) DEL TUMOR. I
BP40092 A FIRST-IN-HUMAN, OPEN-LABEL,MULTICENTER, DOSE-ESCALATION PHASE I CLINICAL STUDY OF SINGLE-AGENT RO7172508 IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC CEA-POSITIVE SOLID TUMORS. I
CO40939 A PHASE Ib, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMAKOKINETICS OF RO6958688 IN COMBINATION WITH ATEZOLIZUMAB AFTER PRETREATMENT WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC, MICROSATELLITE-STABLE COLORECTAL ADENOCARCINOMA WITH HIGH CEACAM5 EXPRESSION. I
MO29518 AN OPEN-LABEL, MULTICOHORT, PHASE II STUDY OF MPDL3280A IN ADVANCED SOLID TUMORS. Basket  
CA017-003-II Estudio fase 1/2a de BMS-986205 administrado en combinación con nivolumab (BMS-936558, anticuerpo monoclonal anti-PD-1) en tumores malignos avanzados. Basket  
TO-TAS0728-101 Estudio multicéntrico, abierto, en fase I/II para investigar la seguridad, farmacocinética y eficacia de TAS0728, un inhibidor oral de la unión covalente de HER2 en sujetos con tumores sólidos avanzados con anomalías en HER2 o HER3. Basket  
I7W-MC-JQBA A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors. I
BP29842 An open-label, multicenter, dose-escalation, Phase I study to evaluate safety, pharmacokinetics, and therapeutic activity of
RO6874281, an immunocytokine consisting of interleukin 2 variant (IL-2v) targeting fibroblast activation protein-á (FAP), in patients with advanced and/or metastatic solid tumors.
I
CA224-020 A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody Nivolumab, BMS-936558) in Advanced Solid Tumors. I
CFAZ053X210 1 Estudio de fase I, abierto, multicéntrico, de escalado de dosis de FAZ053 como agente único y en combinación con PDR001 en pacientes adultos con tumores malignos avanzados. I
204691 Estudio de fase I abierto de GSK3359609 en monoterapia y en combinación con fármacos antineoplásicos en sujetos con determinados tumores sólidos avanzados. I
INCAGN 1949 -101 A Phase 1/2 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors. I
VHIO-PBF-999-01 Phase I/Ib trial of single agent PBF-999 in solid tumour advanced cancer. I
D081EC00001 Estudio en fase I, abierto, de 2 partes, multicéntrico, para evaluar la seguridad, tolerabilidad y eficacia de olaparib en combinación con carboplatino; Parte A: aumento escalonado de la dosis de olaparib en combinación con carboplatino en pacientes con cáncer de mama avanzado HER-2 negativo; seguida de Parte B: fase de expansión de olaparib en combinación con carboplatino para el tratamiento neoadyuvante de pacientes con cáncer de mama avanzado HER-2negativo que presentan mutaciones BRCA1/2 en la línea germinal. I
B9991032 A PHASE 2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH BRCA OR ATM MUTANT TUMORS. Basket
SOLTI-1503 Combination of Talimogene Laherparepvec with Atezolizumab in residual breast cancer following standard neoadjuvant multi-agent chemotherapy (PROMETEO TRIAL). 0
201973 A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer. I
1280.18 Estudio abierto, de fase Ib, de escalado de dosis, para evaluar la seguridad y tolerabilidad de xentuzumab y abemaciclib en pacientes con tumores sólidos localmente avanzados o metastásicos y en combinación con hormonoterapia en pacientes con cáncer de mama localmente avanzado o metastásico positivo para receptores hormonales (RH+) y negativo para HER2, seguido por cohortes de expansión. I
CO40115 A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER (MORPHEUS TNBC). I
D8530C00001 A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast CancerA Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast Cancer. I
CADPT01A12101C A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer. I
ZEN003694-004 A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer. I
CO41012 AA PHASE IB/III STUDY OF IPATASERTIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN HORMONE RECEPTOR POSITIVE AND HER2 NEGATIVE LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER. I
YO39609 A phase Ib/II, open-label, multicenter, randomized, umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer (morpheus-gastric cancer). I
MCLA-128-CL01 A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors. Basket  
BP29889 AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE IB STUDY WITH EXPANSION COHORTS TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND THERAPEUTIC ACTIVITY OF  O7009789 (CD40 AGONISTIC MONOCLONAL ANTIBODY) IN COMBINATION WITH VANUCIZUMAB (ANTI-ANG2 AND ANTI-VEGF BI-SPECIFIC MONOCLONAL ANTIBODY) IN PATIENTS WITH METASTATIC SOLID TUMORS. I
I8X-MC-JECA A Phase 1 Study of LY3200882 in Patients with Solid Tumors. I
GO39932 A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC 9545 Alone or In Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer. I
GO40987 A PHASE I, MULTICENTER, OPEN-LABEL PREOPERATIVE SHORT-TERM WINDOW STUDY OF GDC-9545 IN POSTMENOPAUSAL WOMEN WITH STAGE I-III OPERABLE, ESTROGEN RECEPTOR-POSITIVE BREAST CANCER. I
BAY 1163877 / 19131 An international, multicenter, Phase 1b/2 study of rogaratinib (BAY 1163877) in combination with atezolizumab as first-line treatment in cisplatin-ineligible patients with FGFR-positive locally advanced or metastatic urothelial carcinoma. I
XL184-021 A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors. I
B-701-U22 A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined with Pembrolizumab in Subjects with Locally Advanced or Metastatic Urothelial Carcinoma who have Progressed Following Platinum-basedChemotherapy. I
WO39613 A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY (MORPHEUS-mUC). I
BLU-554-1101 A Phase 1 Study to Assess the Safety, Tolerability,
Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma and Cholangiocarcinoma.
I
CC-122-HCC-002 A PHASE 1/2, MULTICENTER, OPEN-LABEL, DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF CC-122 IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC). I
H3B-6527-G000-101 An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma. I
BAY94-9343/15834 Estudio de fase Ib de múltiples indicaciones con anetumab ravtansina (BAY-94-9343) en pacientes con cáncer
avanzado o recurrente que expresan mesotelina?
I
CTMT212X2106 Estudio fase I/II de seguridad y eficacia de ribociclib (LEE011) en combinación con trametinib (TMT212), en pacientes con tumores sólidos avanzados o metastásicos. I
P-VCNA-001 A phase I, multicenter, open-label, dose escalation study of intravenous administration of VCN-01 oncolytic adenovirus with or without gemcitabine and Abraxane® in patients with advanced solid tumors. I
I5B-MC-JGDP A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer. I
WO39608 A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MORPHEUS-PANCREATIC CANCER). I